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General introduction

General introduction
Hematopoiesis
Every day the human body generates high 
numbers of new blood cells (Ogawa, 13). 
Blood cells arise from immature cells (blasts) 
that reside in the bone marrow, a process 
called hematopoiesis (Figure 1). In the bone 
marrow, the immature cells proliferate, both 
to supply the body with cells that can mature 
into functional blood cells (differentiation) 
and to keep a constant pool of immature 
cells (self-renewal) (Fisher, 2002; Zon, 15; 
Ogawa, 13). The pluripotent stem cell 
population has been defined by its ability 
to reconstitute hematopoiesis in serial bone 
marrow transplantations in mice (Bertoncello 
et al., 188; Lerner and Harrison, 10; 
Ploemacher and Brons, 18). In vitro colony 
forming unit (CFU) assays have identified 
various hematopoietic precursor cells that are 
able to generate a restricted number of blood 
cell types (McCulloch et al., 178; McNiece 
et al., 188; Moore et al., 17; Nakahata 
and Ogawa, 182). Current studies mainly 
use the expression of cell surface markers to 
purify specific cell populations. The stem cell 
can be distinguished by the lack of lineage 
Figure 1. Hematopoiesis. Hematopoietic stem cells, residing in the bone marrow, supply cells that mature 
along different lineages. Cells mature along the myeloid lineage to become erythrocytes (red blood cells), 
megakaryocytes (and platelets), granulocytes or monocytes. Cells mature along the lymphoid lineage to 
become T-cells or B-cells. Alternatively, stem cells may differentiate into megakaryocyte/erythrocyte 
progenitors directly (dotted line).
hematopoietic stem cell
myeloid pathway lymphoid pathway
erythrocytes
megakaryocyte
granulocyte monocyte
B-cell T-cell
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markers and the presence of CD133 (Human 
cells, Lin-CD133+) or c-kit and Sca-1 (murine 
cells, Lin-Ska+Kit+) (Wognum et al., 2003). 
Investigations into the lineage potential have 
suggested the existence of long- and short-
term hematopoietic stem cells, common 
lymphoid progenitors (Kondo et al., 17) 
and common myeloid progenitors (Akashi et 
al., 2000). The common myeloid progenitors 
differentiate into common granulocyte/
monocyte progenitors and megakaryocyte/
erythrocyte progenitors. Alternatively, recent 
studies suggest that the megakaryocyte/
erythrocyte progenitor may originate from 
the short-term repopulating stem cell directly 
(figure 1, dotted line) (Adolfsson et al., 2005). 
The progenitors may mature into several 
types of specialised blood cells, to execute 
their function in immunity (defence against 
infections), coagulation (blood clotting) or 
transport of molecules like oxygen. 
During life, cells may acquire genetic damage. 
Genetically damaged, immature blasts may 
be blocked in their differentiation and these 
cells may fill up the bone marrow and displace 
normal hematopoietic cells. This thesis will 
focus on a subtype of acute myeloid leukemia 
(AML). AML is defined by a more than 20% 
increase of blasts in the bone marrow.
AML
Several types of leukemia can be distinguished, 
depending on what type of blood cell is blocked 
in its differentiation. Cells can originate from 
the lymphoid lineage, resulting in chronic 
or acute lymphoid leukemia (respectively 
CLL or ALL), or from the myeloid lineage, 
resulting in chronic or acute myeloid leukemia 
(respectively CML or AML) (Redaelli et al., 
2003). These types of leukemia are again 
subdivided, depending on the maturation 
stage of the leukemic cells. In the French-
American-British (FAB) classification, 
AML is subdivided in 8 types (AML-M0 
to AML-M7 (Lowenberg et al., 1). 
Recently, the World Health Organization 
(WHO) has developed a new classification 
of hematopoietic neoplasms (Vardiman et al., 
2002). This classification includes many of the 
criteria of the FAB-classifications, which rely 
on morphologic and cytochemical features, 
but also includes immunophenotypic features 
and recurring genetic abnormalities. 
Genetic abnormalities in AML
AML cells often contain chromosomal 
translocations (Figure 2). Translocations may 
result in the fusion of genes that are located 
at the chromosomal breakpoints. Recurrent 
translocations that are found in AML include 
the t(8;21) translocation, resulting in the 
AML-ETO fusion, the t(15;17) translocation, 
resulting in the PML-RARα fusion, the t(16;16) 
translocation or inversion 16, resulting in the 
CBFβ-MYH11 fusion (Gilliland et al., 2004; 
Mrozek et al., 2004; Vardiman et al., 2002). 
There is a strong correlation between certain 
genetic abnormalities and the morphology of 
the leukemic blasts. Genetic abnormalities 
may be used to predict the response to certain 
therapies (Vardiman et al., 2002). 
The genes affected by translocations are 
often involved in the development and 
homeostasis of the normal blood cells and the 
abnormal proteins deregulate proliferation, 
Figure 2. Chromosomal translocations. 
Chromosomes may exchange parts of their 
arms. Breakpoints of chromosomes found in 
APL are almost always found in the PML gene 
on chromosome 15 and in the RARα gene on 
chromosome 17. This translocation results in two 
fusion genes: PML-RARα and RARα-PML.
15 17
PML-RARD RARD-PML
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differentiation or programmed cell death 
(apoptosis) (Taki and Taniwaki, 2006; Mrozek 
et al., 2004; Scandura, 2005). Many of these 
genes encode for transcription factors. Study 
of these transcription factors have shown that 
they are essential in differentiation and lineage 
commitment during hematopoiesis (Tenen, 
2003; Metcalf, 13; Shivdasani and Orkin, 
16; Zhu and Emerson, 2002). 
In addition, transcription factors involved 
in hematopoiesis and leukemia have been 
identified, which are not part of any fusion 
protein. For example, the transcription factors 
PU.1 and C/EBPα have been found to be 
essential factors in the differentiation of the 
myeloid lineage (Nutt et al., 2005; Zhang et 
al., 17). The transcription factor GATA1 has 
been found to be essential for differentiation 
of the erythroid lineage (Pevny et al., 11; 
Weiss et al., 14). Mutations have been 
found in these factors in leukemia. Mutated 
transcription factors are responsible for the 
block in differentiation (Tenen, 2003).
Besides mutations in transcription factors, 
mutations have been found in genes that 
are involved in signal transduction. FLT3, 
a growth factor receptor, is a commonly 
mutated gene in AML (Gilliland et al., 2004). 
Due to this mutation, FLT3 is constitutively 
activated, also in the absence of ligand, and 
is able to confer a proliferate advantage to the 
leukemic cells. 
Thus far, the most commonly mutated gene 
found in AML is nucleophosmin (NPM) (Falini 
et al., 2005). NPM is a tumor-suppressor and 
interacts, amongst others, with p53 (Colombo 
et al., 2002). In other types of cancer, p53 is the 
most frequently mutated oncogene (Vousden 
and Prives, 2005). Instead of mutations in 
the p53 encoding gene, certain regulators of 
p53 are often repressed or overexpressed in 
leukemia, as will be discussed further in this 
thesis (Chapter 4). 
The recurrent mutations described for 
AML are given in table 1 (Mitelman et al., 
2004). These mutations have the following 
significance in the clinic. 1) Several mutations 
have a prognostic value and may be used to 
decide on an appropriate therapy based on a 
more individual risk-assessment (Grimwade 
et al., 18). 2) Mutations may be used as 
molecular tumor markers. Using techniques 
like quantitative PCR, minimal residual 
disease can be monitored (Yin and Grimwade, 
2002). 3) New drugs are being developed 
that target mutated proteins, or the biological 
pathways downstream of this lesion (Deininger 
et al., 2003). 
Some of the recurrent mutations may be 
found together in one leukemic clone. Other 
mutations never occur together. It has been 
inferred that combinations of mutations is 
excluded when the genes, in which these 
mutations occur, function in the same 
biological pathway. A cell with mutations in 
several genes that function in one biological 
pathway will not have a selection advantage. 
For example, the p53 pathway is important 
in tumor suppression. In many cancers, p53 
itself is mutated. A protein like MDM2, a 
regulator of p53, may be affected when p53 is 
not mutated (see also chapter 4 of this thesis). 
In contrast, the PML-RARα translocation is 
often found in combination with a mutation 
in FLT3 (Gale et al., 2005). This indicates that 
both mutations affect a different biological 
pathways.
APL 
Acute promyelocytic leukemia (APL) is a 
subtype of AML (FAB type; AML-M3). APL 
is characterised by a block of differentiation 
in, and accumulation of promyelocytes 
(Sirulnik et al., 2003; Tallman, 2004). 
Before 188, treatment of APL consisted of 
chemotherapy and resulted in long-term free 
survival of approximately 35% of the cases 
1992; Pandolfi et al., 1992). In approximately 
2% of the cases of APL the RARα gene is 
fused to a locus called promyelocytic leukemia 
zinc finger (PLZF) (Chen et al., 13). 
Noteworthy of this class of patients is that 
I12
Table 1 (adepted from Jansen JH and van der Reijden BA, NTvH 2005;2;50-58)
Recurrent mutations in acute myeloid leukemia
Gene(s) Type of 
mutation
Disturbed 
function
Cytogenetics Prognostic 
value
Incidence FAB-
association
BCR
ABL
Gene
fusion
Signal
transduction
t(9;22)(q34;q11) - 1-2% M0
AML1
ETO
Gene
fusion
Transcription
factor
t(8;21)(q22;q22) + 10% M2
CBFE
MYH11
Gene
fusion
Transcription
factor
t(16;16)(p13;q23)
inv(16)(p13;q22)
+ 10% M4Eo
PML
RARD
Gene
fusion
Transcription
factor
t(15;17)(q22;q21) + 5-10% M3
MLL
>30 fusion 
genes
Gene
fusion
Gene
expression
t(11;…)(q23;…) - 10% M4/5
MLL Internal 
duplication
5%
DEK
CAN
Gene
fusion
t(6;9)(p23;q34) - 1-2%
WT-1 Point
mutation
and over 
Expression
Transcription
factor
- 1-5%
N-RAS Point
mutation
Signal 
transduction
- 5-10%
FLT3-ITD Internal 
duplication
Signal 
transduction
- 20-25% M3
FLT3-835 Point
mutation
Signal 
transduction
5%
C/EBPD Point
mutation
Transcription
factor
+ 5%
PU.1 Point
mutation
Transcription
factor
1-5%
c-KIT Point
mutation
Signal 
transduction
1-5% CBF-
leukemia
P53 Point
mutation
Tumor
supressor
1-5%
EVI-1
(several fusion 
genes)
Over
expression 
or gene fusion
Transcription
factor
t(3;...)(q26;...) - 10%
NPM1 Point
mutation
Tumor
supressor
+ 35%
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they do not respond to ATRA with terminal 
differentiation of the cells (Guidez et al., 14; 
Licht et al., 15). Some sporadic cases have 
been described where the RARα gene is fused 
to either nucleophosmin (NPM) (Redner et 
al., 16), nuclear matrix-mitotic apparatus 
protein (NuMa) (Wells et al., 17) or the 
transcriptional activator STAT5b (Arnould et 
al., 1999). The frequently found PML-RARα 
translocation is the main focus of this thesis.
Mouse models of APL
The PML-RARα chimeric protein contains 
most of the PML sequence and a large 
part of RARα, including its DNA and 
nuclear hormone binding domains. The 
reciprocal product, RARα-PML, is not always 
expressed and is believed not to be involved 
in transformation. The role of PML-RARα in 
transformation has been studied by expressing 
the fusion gene in immature hematopoietic 
cells, both in primary bone marrow cells 
in vitro as well as in transgenic animals. 
Expression of PML-RARα resulted in a 
maturation block at the promyelocytic stage 
and inoculation of PML-RARα transduced 
bone marrow cells into irradiated syngenic 
mice resulted in the development of retinoic 
acid sensitive leukemia (Grignani et al., 2000; 
Minucci et al., 2002). Several transgenic 
mouse models were generated in which 
PML-RARα is under the control of a myeloid 
promoter. Transgenic animals developed 
a myeloproliferative syndrome which, 
depending on the promoter that was used, 
progressed to overt leukemia in 30% to 90% 
of the animals after 6-12 months (Pandolfi, 
2001; Pollock et al., 2001; Westervelt et al., 
2003). The incomplete penetrance suggests 
that to develop APL, secondary mutations 
must occur in the transgenic animals. As 
mentioned before, FLT3 may be one of 
these secondary mutations. Introduction of 
an activated form of FLT3 into PML-RARα 
transgenic mice resulted in a decrease in 
latency from 8.5 months to approximately 3 
months (Sohal et al., 2003). Another mutation 
may be the transcription factor PU.1. Some 
human AML samples have an acquired loss-
of-function mutation in one copy of PU.1. 
Crossing haploinsufficient, PU.1+/- mice with 
PML-RARα expressing mice, resulted in an 
increase of the penetrance of APL (Walter et 
al., 2005). 
The RARα transcription factor
ATRA, a derivative of vitamin A, can 
force APL cells to terminally differentiate. 
Paradoxically, it is the vitamin A receptor 
(RARα) that is mutated in APL. To understand 
this paradox, much research has focussed on 
the working mechanism of RARα. RARα 
belongs to the family of nuclear hormone 
receptors. Nuclear hormone receptors 
function as ligand-activated zinc-finger 
transcription factors (Tata, 2002). RARα 
must heterodimerize with another protein, 
RXR, to bind to the DNA. The RARα/RXR 
heterodimer only binds to specific sequences 
in the DNA; the retinoic response element 
(RARE). This element consists of a repeated 
consensus sequence (A/G)G(T/G)TCA that 
is separated by two or five basepairs (deThe 
et al., 10b). Target genes of RARα are 
defined by a RARE within their promoter. In 
the absence of ligand, RARα/RXR represses 
gene transcription by recruitment of co-
repressors (Alland et al., 17; Heinzel et 
al., 17; Nagy et al., 17). Repression 
of gene transcription is by methylation and 
deacetylation (Burgers et al., 2002; Cameron 
et al., 1; Jaenisch and Bird, 2003). 
Methylation of DNA at CpG dinucleotides 
and subsequent recruitment of methyl-
CpG-binding proteins, and deacetylation 
of histones results in remodelling of the 
chromatin structure, making it inaccessible 
to the transcriptional machinery. In the 
presence of ligand, RARα/RXR releases 
the co-repressors and recruits transcriptional 
coactivators with histone acetyltransferase 
activity. Acetylation results in an ‘open’ 
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chromatin structure and renders the DNA 
accessible to the transcriptional machinery 
activating transcription (Glass and Rosenfeld, 
2000; Kouzarides, 1).
PML-RARα is able to bind to the same 
sequences as RARα/RXR and PML-RARα 
is also able to recruit the same co-repressors. 
However, PML-RARα does not release these 
co-repressors under the same conditions as 
RARα/RXR. PML-RARα needs much higher 
concentrations of ATRA to release the co-
repressors and to activate gene transcription 
(Grignani et al., 18; Lin et al., 18; Di 
et al., 2002; Guidez et al., 18; He et al., 
18; Melnick and Licht, 1). Therefore, 
it is believed that under physiological 
concentrations of ATRA, PML-RARα 
represses gene transcription. This repression 
may result in the block of differentiation in 
APL cells. However, under pharmacological 
concentration of ATRA, PML-RARα will 
replace the co-repressors with co-activators 
and activate gene transcription. In this way, 
PML-RARα may force differentiation of 
APL cells.
The PLZF-RARα fusion protein can form, 
via its PLZF moiety, co-repressor complexes 
which are insensitive to ATRA (He et al., 
18). This may explain why PLZF-RARα 
positive cells do not differentiate in response 
to ATRA.
The PML protein
PML was first described as the fusion partner 
of RARα in the t(15;17) translocation in APL, 
hence the name promyelocytic leukemia gene 
(PML). However, PML expression is not 
limited to APL cells. PML is a ubiquitously 
expressed protein (Borden, 2002). Typically, 
PML is localised to the cell nucleus and is 
concentrated in round dots (±10 per cell, 
figure 3). These domains are called nuclear 
bodies (PML-NBs) and were first observed as 
early as the 160s using electron microscopy. 
In APL cells the nuclear bodies are disrupted 
and appear dispersed into many, smaller, 
microspeckles (Figure 3). Treatment of APL 
cells with ATRA restores the localisation of 
PML into macrospeckles (Weis et al., 14).
Knowledge of the exact function of the 
PML-NBs, and of the microspeckles, remains 
incomplete. Over 50 protein partners, with 
a wide variety of functions, have been 
described for PML. These include chromatin 
remodelling factors, DNA replication factors, 
translation initiation factor 4E (eIF4E), 
SUMO-related proteins and the apoptosis 
related proteins p53 and MDM2 (Borden, 
2002). Therefore, PML may function in 
transcription, DNA repair, DNA replication 
and mRNA transport. Noteworthy, DNA 
viruses start their replicative processes in PML 
bodies (Tang et al., 2003).
Disruption of PML-NBs through mutation 
of the RING-domain of PML is correlated 
with a loss of its growth suppression activity 
(Le et al., 16), loss of apoptotic activity 
(Borden et al., 18), and inability to transport 
certain mRNAs (Lai and Borden, 2000). 
Overexpression of PML in serum-starved 
fibroblasts induces apoptosis (Borden et al., 
17). 
Mouse models have shown that the PML gene 
is not essential for survival. However, PML is 
essential for apoptosis induced under several 
types of cellular stresses (Wang et al., 18). 
In addition, PML -/- mice are highly susceptible 
to infections. However, these mice develop, 
in a sterile environment, within 15 months, 
cancer with 100% penetrance (Unpublished, 
Pandolfi PP 4th international symposium on 
APL, Rome, 2005). 
Not all of the PML protein is localised in the 
nucleus, some is localised in the cytoplasm. 
Cytoplasmic PML has been shown to be an 
essential modulator of the TGF-β signalling 
pathway, which is an important tumour 
suppressive pathway (Lin et al., 2004). 
General introduction
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Mechanisms of transformation and 
terminal differentiation in APL
PML-RARα is the causitive oncogene in 
APL. Treatment with ATRA forces terminal 
differentiation of APL cells. Differentiation 
of APL cells, in response to ATRA, is 
accompanied by degradation of the PML-
RARα oncoprotein. 
Two processes may be involved in terminal 
differentiation of APL cells. Firstly, ATRA 
may activate PML-RARα-dependent gene 
transcription, thereby actively inducing 
differentiation. Secondly, degradation of 
PML-RARα may result in cancellation of the 
dominant negative effects of PML-RARα, in 
other words: induction of differentiation by 
reversal of the transforming effects. In this 
thesis we describe the studies we have done 
into the processes of transformation and 
differentiation (Figure 4). 
P M L - R A Rα  a n d  m e c h a n i s m s  o f 
transformation
PML-RARα is able to bind to RARα target 
genes and is able to repress transcription 
of these genes. As described above, this 
Figure 3. APL cells. (A) May-Grünwald-Giemsa 
staining; Cells were isolated from an APL patient 
at diagnosis and after 23 days of ATRA therapy 
(without chemotherapy). Before treatment a 
high percentage of promyelocytic blasts is 
found. During treatment, increasing amounts of 
maturing granulocytes are found. At day 23, many 
cells have both a granulocytic-like nucleus and 
auer rods, typical for APL cells. This indicates 
that the leukemic cells have differentiated (B) 
A
B                          C
PML-CFP
PML-RARD-CFPPML-RARD PML
Diagnosis ATRA (23 days)
Immunofluorescence; APL cells, at diagnosis, and 
non-APL cells were stained with anti-PML specific 
antibody. PML is found in the nucleus of every 
cell and is localised in about 10 dots, called PML 
nuclear bodies. PML(-RARα) is dispersed in APL 
cells into smaller dots, called microspeckles. (C) In 
the upper panel PML, fused to ECFP, is expressed 
in HEK23 cells (1 cell is shown). In the lower 
panel PML-RARα, fused to ECFP, is expressed in 
HEK23 cells (2 cells are shown).
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theory may explain some of the oncogenic 
properties of PML-RARα. However, several 
other properties of PML-RARα may add 
to its oncogenicity: (1) Besides disturbing 
RARα function, PML-RARα disturbs PML 
localisation and function. For example, it has 
been shown that the TGF-β signalling pathway 
is disturbed in PML-RARα expressing cells, 
comparable to PML -/- cells (Lin et al., 18). 
(2) The p53 protein is the main executioner 
of apoptosis. PML-RARα expression impairs 
p53 stability and function (Insinga et al., 
2004), making APL cells insensitive to p53-
mediated apoptosis. (3) PML-RARα can 
bind to a larger variety of direct repeats than 
RARα (Kamashev et al., 2004; Jansen et al., 
15). This suggests that PML-RARα has 
additional targets over RARα. (4) Besides 
(de-)regulating transcription, PML-RARα 
stabilizes the kinase MNK1, at the protein 
level (Worch et al., 2004). Stabilization of 
proto-oncoproteins may contribute to the 
transformation of APL. (5) PML-RARα 
sequesters RXR to the microspeckles (Weis et 
al., 14). Beside a heterodimerisation partner 
for RARα, RXR is a heterodimerisation 
partner for many nuclear hormone receptors 
(Chambon, 16). PML-RARα may block 
the function of these other nuclear hormone 
receptors by sequestering RXR.
The oncogenicity of PML-RARα is dependent 
on certain criteria. (1) The capability to block 
differentiation is dependent on the presence 
of both the dimerization domain in the PML-
part as well as the DNA binding domain in 
the RARα-part of PML-RARα (Grignani et 
al., 16; Kastner et al., 12; Perez et al., 
13). (2) A sumoylation site (K160) in the 
PML-part of PML-RARα is essential to fully 
develop APL (Zhu et al., 2005). This site is 
essential for the binding of PML-RARα to 
several proteins, suggesting these binding 
partners are needed for transformation. (3) 
The transforming capacity of PML-RARα 
depends on the presence of the myeloid 
specific serine protease; neutrophil elastase 
(Lane and Ley, 2003; Lane and Ley, 2005). 
This enzyme is able to cleave the PML-RARα 
protein. These findings may be explained by 
the fact that PML-RARα expression is toxic 
in most cell types. Low expression levels 
however, of PML-RARα, are probably 
transforming.
PML-RARα in differentiation
Several lines of evidence support the idea that 
PML-RARα mediates the ATRA response in 
APL cells and actively induces differentiation. 
PML-RARα is able to bind to ATRA and 
activate transcription upon ATRA binding. 
PML-RARα increases the sensitivity to ATRA 
when expressed in non-APL cells and restores 
ATRA-sensitivity in cell lines carrying 
mutations in RARα (Grignani et al., 13; 
Grignani et al., 16; Ruthardt et al., 17). 
PML-RARα re-expression restores ATRA-
sensitivity in APL cells with constitutive 
degradation of the fusion protein (Fanelli et 
al., 1). 
Additionally, PML-RARα is degraded in 
APL cells after the ATRA response, a process 
that starts later than 12 hours after the initial 
exposure to ATRA. Release of the dominant 
negative effect on several signalling pathways 
may drive the APL cells into terminal 
differentiation (See chapter 7 “summary and 
perspectives” for an extensive discussion on 
transformation and differentiation in APL). 
Figure 4. APL may be used to study both the 
process of transformation and differentiation in 
one disease.
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PML-RARα target genes
Several groups have employed microarrays 
to identify the genes regulated by PML-
RARα and ATRA, using fresh APL cells 
(Meani et al., 2005), using the APL derived 
-PML-RARα positive- cell line NB4 (Lee 
et al., 2002; Liu et al., 2000; Nouzova et al., 
2004; Tamayo et al., 1; Thompson et al., 
2003), or using U37 cells expressing PML-
RARα under the control of a Zn2+ inducible 
promoter (Alcalay et al., 2003; Meani et al., 
2005; Muller-Tidow et al., 2004; Park et al., 
2003). 
Ectopic expression of PML-RARα in U37 
cells results in the downregulation of several 
genes. These genes include genes normally 
involved in commitment to the granulocytic 
lineage; C/EBPα, JUND, GFI1, CSF3R, 
STAT5A, HCK, ZNF1A1, to the erythroid 
lineage; NFE2 and to the lymphoid lineage; 
STAT5A, TCF3. These targets may cause the 
differentiation block. Moreover, 17 DNA 
repair genes were found downregulated 
by PML-RARα. This may increase the 
susceptibility of APL cells to additional 
mutations.
Ectopic expression of PML-RARα also 
results in upregulation of several genes. 
These targets include BCL11A, LMO1 and 
JAG1, which are implicated in self-renewal of 
hematopoietic stem cells. The studies revealed 
that PML-RARα expression may activate the 
NOTCH and WNT signalling pathways. Both 
the downregulation and the upregulation of 
genes by PML-RARα are counteracted by 
ATRA.
In U37 cells, several genes are only 
responsive to ATRA when PML-RARα is 
expressed. This suggests that these targets are 
not transcriptionally regulated by wild-type 
RARα. Treating cells with cycloheximide, 
an inhibitor of protein synthesis, does not 
inhibit the ATRA response of several of 
these genes. This suggests that PML-RARα 
directly regulates these genes. Together these 
data indicate that PML-RARα regulates a set 
of genes that are not regulated by wild-type 
RARα. 
helix-loop-helix (HLH) proteins
Members of the bHLH family of transcription 
factors have been implicated in cell fate 
decisions in many different tissues. For 
example, the bHLH transcription factors 
MyoD and myogenin are involved in the 
development of muscle tissue and during 
neurogenesis the bHLH protein MASH-1 
plays an essential role (Massar et al., 2000). 
As a common theme, tissue specific bHLH 
factors form heterodimers with members of 
the more ubiquitously expressed E-protein 
bHLH family members E12/47, HEB and 
E2-2, which are generally considered as 
promiscuous heterodimerization partners. 
Inhibitors of DNA binding (ID) proteins 
constitute a separate class of HLH proteins 
lacking the basic DNA-binding domain 
and acting as dominant negative regulators 
of bHLH transcription factors by trapping 
them in heterodimeric complexes which are 
unable to bind DNA (Massar et al., 2000). In 
addition, ID proteins have been implicated in 
cell cycle control through direct interaction 
with the retinoblastoma protein (Norton 
et al., 2000), and by interaction with the 
centrosome (Hasskarl et al., 2004). Recent 
data indicate the involvement of ID proteins 
in angiogenesis, metastasis and tumorigenesis 
(de Candia et al., 2003; Fong et al., 2003; 
Ruzinova et al., 2003; Sikder et al., 2003). In 
hematopoiesis, bHLH transcription factors 
and their dominant negative regulators, 
the ID proteins, have been implicated in 
lymphopoiesis. Constitutive expression of 
ID1 targeted to pro-B cells in transgenic 
mice revealed impairment of B lymphocyte 
development (Norton et al., 18). In addition, 
several mutations affecting bHLH proteins 
have been implicated in lymphoid leukemia. 
Three bHLH family members (SCL/TAL-
1, LYL-1 and E2A) are located at the sites 
of recurrent chromosomal translocation 
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breakpoints in leukemia. The t(1;14) in 
patients with T cell acute lymphoblastic 
leukemia (T-ALL) transposes the SCL gene 
to the TCR alpha/delta locus on chromosome 
14 (Begley et al., 18). The t(7;1) in T-ALL 
involves the LYL-1 gene that is translocated to 
the TCR beta locus (Mellentin et al., 18a). 
E2A is involved in the t(1;1) that occurs in 
approximately 25% of the cases of childhood 
pre-B ALL and results in the generation  of 
an E2A-PBX fusion protein (Mellentin et 
al., 18b). 
We have found that certain HLH proteins are 
responsive to ATRA (Nigten et al., 2005). 
ATRA induced a rapid increase in ID1 and 
ID2, both in the APL cell line NB4 as well as 
in primary patient cells. In addition, a strong 
downregulation of E2A was observed. The 
simultaneous upregulation of ID1 and ID2, 
and the downregulation of E2A suggest 
a role for bHLH proteins in the induction 
of differentiation of APL cells following 
ATRA treatment. To test the relevance 
of this upregulation, ID1 and ID2 were 
overexpressed in NB4 cells. Overexpression 
inhibited proliferation and induced a G0/G1 
accumulation. These results indicate that 
ID1 and ID2 are important retinoic acid 
responsive genes in APL, and suggest that 
the inhibition of specific bHLH transcription 
factor complexes may play a role in the 
therapeutic effect of ATRA in APL.
Gain-of-function
PML-RARα is able to act as a double 
dominant-negative protein, inhibiting the 
normal activity of both PML and RARα. 
Artificial RARα fusion proteins have been 
generated in which the PML part was replaced 
with a dimerizing peptide (Matsushita et al., 
2006; Sternsdorf et al., 2006). In vivo, these 
constructs induced leukemia with very low 
efficiency, suggesting disruption of RARα is 
not sufficient for leukemogenesis. Crossing of 
the lines expressing the artificial RARα fusion 
proteins into PML null background did not 
result in an increased incidence of leukemia. 
These data suggest that PML-RARα does not 
simply block PML and RARα function, but 
rather that the fusion gene represents a gain-
of-function. 
Expression of PML-RARα in the myeloid 
cell line U37 enhances its sensitivity to the 
induction of differentiation by ATRA and 
several genes are only responsive to ATRA 
when PML-RARα is expressed. This suggests 
that also during differentiation PML-RARα 
may represent a gain-of-function mutation.
We investigated the mechanism by which ID1 
and ID2 are regulated in APL cells. We found 
that ID1 and ID2 are regulated by PML-RARα 
through a novel mechanism, which is not 
shared with normal RARα, defining a gain-of-
function through an as yet not recognized class 
of genes directly upregulated upon ATRA-
induced differentiation of APL cells. 
We found that the transcription factor NF-Y is 
involved in the gain-of-function mechanism 
in APL. Therefore we also investigated the 
function of this factor in normal hematopoiesis 
and we describe how NF-Y is involved in 
regulating the expansion of the myeloid 
progenitor cells. Additionally, we developed 
a novel protocol to investigate protein-protein 
interaction in a high-throughput manner using 
the different NF-Y protein subunits. 
Furthermore we investigated the effect of 
PML-RARα on the p53 apoptotic pathway. 
We describe a novel link between PML-RARα 
and the p53 inhibitor MDM2 and show that 
MDM2 inhibitors may have therapeutic use 
in APL. 
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Gene transactivation without direct DNA-binding defines a 
novel gain-of-function for PML-RARα
Abstract
PML-RARα is the causative oncogene in 5-10% of the cases of acute myeloid leukemia. 
At physiological concentrations of retinoic acid PML-RARα silences RARα target genes, 
blocking differentiation of the cells. At high concentrations of ligand, it (re)activates the 
transcription of target genes, forcing terminal differentiation. The study of RARα target 
genes that mediate this differentiation has identified several genes that are important for 
proliferation and differentiation control in normal and malignant hematopoietic cells. 
In this chapter we show that the PML-RARα fusion protein not only interferes with 
the transcription of regular RARα target genes. We show that the ID1, ID2 and HES1 
promoters are activated by PML-RARα but, unexpectedly, not by wild type RARα/RXR. 
Our data support a model in which the PML-RARα fusion protein regulates a novel 
class of target genes by interaction with the Sp1 and NF-Y transcription factors, without 
directly binding to the DNA, defining a gain-of-function for the oncoprotein.
Introduction
Acute promyelocytic leukemia (APL) is 
characterized by an excess of immature 
promyelocytes in the bone marrow that fail to 
differentiate towards mature granulocytes. In 
approximately 98% of the cases, the retinoic 
acid receptor-α (RARα) gene is fused to the 
promyelocytic leukemia (PML) gene resulting 
in a PML-RARα fusion protein. The PML-
RARα chimeric protein contains most of the 
PML sequence and a large part of RARα, 
including its DNA- and nuclear hormone-
binding domains. APL blasts can be forced to 
terminally differentiate using pharmacological 
doses of all-trans retinoic acid (ATRA). 
When treated with chemotherapy, APL 
patients can be cured in approximately 40% 
of the cases. The combination of ATRA with 
chemotherapy leads to a remarkably high cure 
rate of approximately 90% [1, 2], and APL 
currently represents the best prognostic group 
amongst the different forms of leukemia. This 
treatment constitutes one of the first examples 
of successful induction of differentiation of 
malignant cells yielding significant clinical 
results.
The role of PML-RARα in transformation 
and terminal differentiation has been studied 
intensively in the past decade. PML-RARα 
was shown to act as a dominant oncogene, 
interfering with the normal function of the 
unrearranged PML as well as the unrearranged 
RARα protein. Expression of the fusion protein 
in immature hematopoietic cells induced a 
maturation block at the promyelocytic stage. 
Inoculation of PML-RARα-transduced 
bone marrow cells into irradiated syngenic 
mice resulted in the development of retinoic 
acid sensitive leukemia [3, 4]. Furthermore, 
PML-RARα transgenic mice developed 
a myeloproliferative syndrome which 
progressed to overt leukemia in 30% to 90% 
of the animals after 6-12 months, depending 
on the promoter that was used [5-7].
PML is a ubiquitously expressed protein that 
localizes to nuclear substructures termed 
nuclear bodies. More than 50 protein partners 
with various biological functions colocalize 
with PML [8]. In APL cells these nuclear 
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bodies are disrupted and dispersed into 
numerous small microspeckles [9]. PML 
has multiple tumor-suppressor functions and 
is involved in growth control, replicative 
senescence and apoptosis [10]. PML -/- mice 
are prone to develop tumors in response to 
various forms of stress. In addition, PML-
RARα transgenic mice develop leukemia 
much faster in a PML -/- background [11].
Retinoic acid receptors are transcription 
factors that activate genes in a ligand-
dependent manner. RARα binds to DNA 
as a heterodimer with RXR proteins. In the 
absence of ligand, both RARα/RXR and 
PML-RARα bind corepressors like N-Cor 
and SMRT and recruit histone deacetylases 
leading to gene silencing. In the presence 
of ligand, the corepressors are replaced 
by coactivators, leading to transcriptional 
activation. However, PML-RARα releases the 
corepressors at much higher concentrations 
of ligand compared to the unrearranged 
receptors. Since PML-RARα competes with 
unrearranged receptors for the same DNA-
binding sites, the presence of the fusion protein 
results in dominant silencing of retinoic 
acid receptor target genes at physiological 
concentrations of ligand. At higher, supra-
physiological concentrations the fusion 
protein can still function as a transcriptional 
activator releasing the corepressor complex 
and allowing the transcription of genes that 
are important for granulocytic differentiation 
[12-15]. The release of the differentiation 
block by high concentrations of retinoic acid 
leads to terminal granulocytic differentiation 
of the leukemic cells and the induction of 
hematological remissions in the patients. 
RARα target genes are not restricted to 
genes that contain a consensus retinoic 
acid receptor binding-site in their promoter. 
Liganded RARα is able to repress AP-1 
mediated transcription [16-18]. PML-RARα 
abnormally regulates AP-1 activity as it 
stimulates AP-1-dependent transcription in the 
presence of ligand, whereas unliganded PML-
RARα inhibits AP-1 dependent transcription 
[19]. In addition, RARα may interfere with 
GATA-2-dependent transcription. Liganded 
RARα enhances GATA-2-dependent gene 
transcription via direct protein-protein 
interaction [20]. This activity is retained in the 
PML-RARα fusion protein [21]. Furthermore, 
interaction of normal retinoid receptors with 
the transcription factor Sp1 has been shown 
[22, 23]. Together, the data support a model 
in which PML-RARα interferes with RARα 
target gene expression in a dominant fashion, 
and that restoration of target gene expression 
by high concentrations of ligand is important 
for the induction of differentiation.
Apart from interference with the function of 
both parental proteins in a dominant negative 
manner, a gain-of–function for PML-RARα 
is suggested by various observations. PML-
RARα may bind to DNA as a heterodimer 
with RXR, but also independently from RXR 
as a homodimer [24]. It may bind to regular 
retinoic acid receptor binding sites consisting 
of a repeated consensus [(A/G)G(T/G)TCA] 
sequence, but the required spacing between the 
two half-sites is less stringent for the fusion 
protein. This allows the fusion protein to bind 
to a wider range of DNA-target sequences 
compared to normal receptors [25, 26]. The 
importance of PML-RARα as a transcriptional 
activator of differentiation-inducing genes was 
shown by in vitro experiments. Expression of 
PML-RARα in the myeloid cell line U937 
(that also expresses normal retinoic acid 
receptors) enhanced their sensitivity to the 
induction of differentiation by ATRA [27]. In 
addition, forced expression of PML-RARα, 
but not RARα, in an ATRA resistant APL 
cell line with constitutive degradation of the 
chimeric protein restored ATRA sensitivity 
[28]. Importantly, in APL patients that became 
resistant to differentiation induction with 
ATRA during therapy, additional mutations 
were found in the ligand-binding domain of 
the RARα part of the PML-RARα fusion 
protein, indicating an important role for 
a novel gain-of-function for PML-RARα
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the fusion protein during the retinoic acid-
induced differentiation of the leukemic cells 
[29]. Finally, experimental mouse models in 
which various natural and artificial RARα 
fusion proteins were expressed also support 
a model in which interference with the 
function of RARα and PML is important, 
but in addition, they suggest that the PML-
RARα fusion protein exhibits gain-of function 
characteristics, unique to the fusion protein 
[7, 30]. So far, the mechanisms behind these 
observations remain largely unclear.
We have previously shown that  the 
transcription factor inhibitors ID1 and ID2 
are upregulated upon treatment with ATRA 
and play a role in cell cycle arrest during 
APL differentiation [31]. In this study we 
investigated the mechanism by which these 
genes are regulated in APL cells. We found 
that ID1 and ID2 are regulated by PML-RARα 
through a novel mechanism, which is not 
shared with normal RARα, defining an as yet 
unrecognized class of retinoic acid-induced 
genes in APL.
Materials and Methods 
Cell culture 
NB4 cells, U937 and U937-PR9 cells 
(kindly provided by Dr. P.G. Pelicci and Dr. 
F. Grignani) were cultured in RPMI 1640 
medium (Gibco, Gaithersburg, MD), Hep3B 
cells in IMDM (Gibco) and HEK293 cells in 
DMEM + 2 mM L-glutamine. Media were 
supplemented with 10% FCS (Gibco). ATRA 
was used at a final concentration of 10-6 M 
(Sigma, St Louis, MO) and ZnSO4 at 100µM. 
Cycloheximide (ICN, Costa Mesa, CA) was 
added 30 min. prior to ATRA at 4 µg/ml.
DNA constructs and antibodies 
The human ID1 promoter was obtained from 
J. Campisi (University of California, USA). 
The ID2 promoter [32] was cloned into 
the XhoI-HindIII sites of the pGL3-basic 
vector (Promega, Madison WI, USA) after 
amplification with the following primers: sense 5’- 
GTACGGTACCTCGAGTTGGGCATGGT
TTGCAATA, and anti-sense 5’-GTACAGA
TCTAAGCTTGAAGCCCGAGCCCGGC.
 The HES1 promoter (containing the –252 to 
+31 promoter fragment of HES1) was cloned
 into the XhoI-HindIII site of the pGL3-basic
vector (Promega) after amplification with the
following primers: sense 5’- GTACCTCGA
GGAGAGTAGCAAAGGGTTAAAATCCT,
anti-sense 5’-GTACAAGCTTCTGTTATC
AGCACCAGCTCCG. RARE3-tk-luc [33], 
PML-RARα∆R [34] and PML-RARα∆CC, 
PML-RARα, RARα and RXR expression 
constructs [25] were as described. FLAG-
PML-RARα was from A. Tomita [35] and 
was recloned into a CMV-expression vector. 
ID1 promoter deletion/mutation fragments 
were constructed by PCR and cloned into the 
XhoI-HindIII sides of PGL3-basic (Promega). 
All constructs were sequence verified. The 
dominant negative NF-YA (YAm29) construct 
and anti-NF-YB polyclonal antiserum were 
from R. Mantovani (University of Milan, 
Italy). pGEX- Sp1 was from H. Rotheneder 
(University of Vienna, Austria). Anti-Sp1 
(PEP-2), anti-NF-YA (H-209), anti-RARα 
(C-20) and anti-ID1 (Z-8) antibodies were 
purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-PML rabbit antibody 
was as described [9]. Anti-FLAG (M2) 
antibody was from Sigma. Anti-murine HES1 
rabbit polyclonal antibody was a kind gift 
from Dr. Tetsuo Sudo, Toray Industries, Inc., 
Japan. As a control in the ChIP experiments, 
human IgG was used (Ivegam, Sanquin, The 
Netherlands).
Northern blotting 
Total cellular RNA was isolated by guanidium-
isothiocyanate lysis and centrifugation on 
a 5.7 M cesium chloride cushion. 10µg of 
total RNA was size-fractionated by 1% 
agarose-formaldehyde gel electrophoresis and 
transferred onto Hybond N+ nylon membranes 
(Amersham, Buckinghamshire, UK). Filters 
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were hybridized at 65°C overnight in phosphate 
buffer (2N NaH2PO4, 7% sodium dodecyl 
sulphate (SDS), 1 mM EDTA pH 8 and 1% 
BSA). DNA probes were labeled with [32P]α-
dATP by random primed labeling (Boehringer, 
Mannheim, Germany). After hybridization, 
filters were washed in 0.2xSSC/0.2% SDS 
for 15 minutes at 65°C. Northern blots were 
hybridized to radiolabeled human ID1 or ID2 
probes (kindly provided by Dr. S. Stegman). 
As a control for equal loading, filters were 
stripped and hybridized to a 777bp HindIII-
EcoRI human GAPDH fragment. 
Transactivation studies 
Cells were transfected using calcium-
phosphate precipitates with 0.25 µg pGL3-
ID1 or -ID2 promoter, 0.05 µg nuclear 
receptor expression vector, 0.1 µg of Renilla 
vector (pRL-CMV, Promega) and 1 µg YAm29 
expression vector. The total amount of DNA 
was normalized to 1.4 µg for all transfections 
using empty vectors. Cells were harvested 
16 hours after ATRA treatment using 100µl 
Passive Lysis Buffer (Promega). Firefly 
luciferase and Renilla luciferase activities 
were measured on a luminometer (Lumat LB 
9507, Perkin-Elmer/Applied Biosystems, CA, 
USA) using Dual-Luciferase Reporter Assay 
System reagents (Promega). 
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described 
[36]. 5 µg was incubated in a total volume 
of 15 µl containing 1 µg of double stranded 
poly(dI)-poly(dC), 10mM Hepes, 50mM 
KCL, 1 mM DTT, 1 mM PMSF, 2.5 mM 
MgCl2, 10% (w/v) glycerol, 300 µg/ml 
BSA and 0.5 ng of a labeled double 
stranded oligonucleotide probe: ID1 5’-
CCGCCCATTGGCTGCTTTTGAACGT. 
To show specificity of binding, non-
labeled 100 fold excess of double-stranded 
oligonucleotides were added to compete 
for binding with the labeled probe. For this, 
either the ID1 probe (self competition), a 
sequence not containing any CCAAT box 5’-
TCAGAGTTCAAGGTTCTAGTCGCTGC
GGC, or a NF-Y binding site containing 
oligonucleotide from the CD 10 gene was used 5’-
ATCCCGACCAATGAGCGCACGGGGCC
GGGT [37]. DNA-protein complexes 
were resolved on a 5% non-denaturing 
polyacrylamide gel in 0.5xTBE buffer.
GST pull-down 
GST-fusion proteins were produced in E.coli 
BL21 which were induced at A600 = 0.5 with 
300 µM IPTG for 4 hours. Proteins were 
released by sonication and loaded onto 
glutathion-agarose (Sigma) by incubation at 
4ºC for 2 hours in lysis buffer (0.15 M NaCl, 
50 mM Tris [pH 8.3], 10 mM EDTA, 0.5% 
NP40 and protease inhibitors). Pull-down 
was performed using in vitro translated PML-
RARα and PML-RARα∆cc (reticulocyte 
lysate, Promega) or rHSp1 (Promega), by 2 
hours incubation at 4°C. Beads were washed 
in lysis buffer and subsequently resuspended 
in SDS-loading buffer.
Chromatin immunoprecipitation (ChIP) 
DNA-protein cross-linking was done for 
30 min at room temperature by adding 
formaldehyde at a final concentration of 1% 
directly to the culture medium. Cross-linking 
was stopped by the addition of glycine to a 
final concentration of 125 mM. Cells were 
washed with ice-cold phosphate-buffered 
saline, buffer B (10 mM EDTA, 0.5 mM 
EGTA, 0.25% Triton X-100, 20 mM HEPES 
[pH 7.6]), buffer C (1 mM EDTA, 0.5 mM 
EGTA, 0.15 M NaCl, 50 mM HEPES [pH 7.6] 
) and resuspended in incubation buffer (0.15% 
SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM 
EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 
7.6] and protease inhibitors) at 33x106 cells/ml. 
Chromatin was sonicated using the Bioruptor 
(Cosmo Bio, Tokyo, Japan), at high intensity 
for 15 min with 0.5 min. intervals. Insoluble 
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material was removed by centrifugation at 4°C 
for 15 min. 120 µl supernatant was incubated 
with 30 µl precoated protein A/G plus agarose 
beads 50% v/v (SantaCruz), 0.1% BSA, 36 
µl 5x incubation buffer, protease inhibitors 
and 2-5 µg antibody (anti-NF-YA, anti-PML, 
anti-FLAG or non-specific IgG from human 
serum) and rocked at 4°C for 16 hours. 
Beads were harvested by centrifugation and 
washed twice with buffer 1 (0.1% SDS, 0.1% 
NaDOC, 1% Triton X-100, 0.15 M NaCl, 
1 mM EDTA, 0.5 mM EGTA and 20 mM 
HEPES [pH 7.6]), once with buffer 2 (0.1% 
SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 
M NaCl, 1 mM EDTA, 0.5 mM EGTA and 
20 mM HEPES [pH 7.6]), once with buffer 3 
(0.25 M LiCL, 0.5% NaDOC, 0.5% NP-40, 1 
mM EDTA, 0.5 mM EGTA, 20 mM HEPES 
[pH 7.6]), and twice with buffer 4 (1 mM 
EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 
7.6]). Chromatin antibody complexes were 
eluted by the addition of 1% SDS and 0.1 M 
NaHCO3 to the pellet and incubated for 20 
min. at room temperature. Cross-linking was 
reversed by the addition of NaCl (0.44 M final 
conc.) and incubation of the eluted samples for 
at least 4 h. at 65°C. DNA was recovered by 
phenol-chloroform-isoamylalcohol extraction 
followed by chloroform-isoamylalcohol 
extraction and precipitated by the addition of 
0.1 volume of 1 M sodium acetate (pH 5.2), 
and 2.5 volumes of ethanol. Precipitated DNA 
was dissolved in water, and input as well as 
immunoprecipitated DNA was analyzed using 
quantitative PCR for genomic sequences 
from the ID1, ID2, RARβ and p21 promoter 
regions [38]. 
Quantitative PCR 
Quantitative PCR to measure ID1, ID2 and 
HES1 mRNA expression was performed with 
the ABI/PRISM 7700 Sequence Detection 
system (ABI/PE, Foster City, Ca, USA). As a 
reference gene PBGD was used. The primer/
probe sequences for the ID1 gene were: 
sense 5’-
GTTACTCACGCCTCAAGGAGCT, 
anti-sense 5’-
GAGAATCTCCACCTTGCTCACC, 
probe FAM 5’-
CCCACCCTGCCCCAGAACCG; 
for ID2: sense 5’-
GACTGCTACTCCAAGCTCAAGGA, 
anti-sense 5’-
CGTGCTGCAGGATTTCCAT, 
probe FAM 5’-
CCCAGCATCCCCCAGAACAAGAAGG; 
for HES1: sense 5’-
GAAGGCGGACATTCTGGAAA,
anti-sense 5’-
GCGGGTCACCTCGTTCAT. 
PCRs were done in a 50µl reaction mixture 
(1.25 U AmpliTaq Gold, 1xbuffer A (both 
Perkin-Elmer), 250 mM dNTPs (Pharmacia) 
and 5 mM MgCl2, for 10 min. at 95°C followed 
by 45 cycles of 15 sec. at 95°C and 1 min. 
at 62°C. Quantitative PCR following ChIP 
was done using Sybr Green PCR (Applied 
Biosystems). Primer sequences for the ID1 
promoter were; 
sense 5’- 
CACTGCGAGCAGGCACTAGAC, 
anti-sense 5’-
AGCCACAGCTTGTCTTT; 
for the ID2 promoter; sense 5’-
CTGTACTCTATTTACCACCCCAGCTG 
and anti-sense 5’-
GGCGTGGGCTTGGTTCTT; 
for the RARβ promoter; sense 5’-
TTGGGTCATTTGAAGGTTAGCA, 
anti-sense 5’-
CACACAGAATGAAAGATTGAATTGC, 
for the p21 gene sense 5’-
GGCGGGGCGGTTGTAT 
and anti-sense 5’-
AAGGAACTGACTTCGGCAGC. 
for the HES1 promoter; sense 5’-
AGTCAAAGCAGCTCTGTTACATATGAG,
anti-sense 5’-
TTTGGTCTTGATCTTGTCTATTTCTTTT.
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Results 
ID1 and ID2 are direct retinoic acid-
responsive genes in APL cells 
Basic helix-loop-helix (bHLH) transcription 
factors and their inhibitors, ID proteins, play 
crucial roles in the regulation of differentiation 
in various cell types. We have shown that ID1 
and ID2 are upregulated in APL cells upon 
exposure to ATRA [31]. Upregulation of ID1 
and ID2 mRNA was confirmed with qPCR 
(Figure 1A and B), showing clear upregulation 
within 4 hours after the addition of ATRA. To 
investigate whether ID1 and ID2 were directly 
upregulated by ATRA, cells were treated 
with cycloheximide prior to the addition of 
ATRA to inhibit protein translation. Both 
ID1 and ID2 mRNAs were upregulated 
within 0.5 hours by ATRA, regardless of the 
addition of cycloheximide (Figure 1C and D). 
This indicates that both genes were directly 
upregulated, without intermediate protein 
production. 
The ID1 upstream promoter is transactivated 
by PML-RARα but not by RARα/RXR
To identify the regulatory DNA sequences 
through which the induction of ID1 by 
retinoic acid was mediated, we analyzed 
the 5’ upstream promoter sequence in 
transactivation assays. A 963 bp fragment of 
the promoter, including the putative TATA 
box, was cloned into a luciferase reporter 
construct. When expressed alone, RARα, 
RXR and PML were not able to transactivate 
the ID1 promoter both in the absence and 
presence of ATRA (Figure 2A). In contrast, 
PML-RARα transactivated the promoter more 
than 12-fold in an ATRA-dependent fashion. 
Surprisingly, the combination of RARα/RXR 
Figure 1. ID1 and ID2 are direct retinoic acid 
target genes in NB4 cells. Quantitative PCR and 
Northern blot analysis of NB4 cells treated with 
ATRA. mRNA was isolated from NB4 cells and 
ID1 (A) and ID2 expression (B) were determined 
using specific primers and probes by quantitative 
PCR (n=4). Quantities were normalized based 
on β-actin expression. To investigate whether 
the induction of ID1 and ID2 was dependent on 
intermediate protein production, cells were treated 
with cycloheximide alone (4µg/ml) or with the 
combination of cycloheximide and ATRA (10-6 M). 
Blots were hybridized using radiolabeled ID1- (C) 
and ID2-specific (D) probes. As a control for equal 
loading blots were stripped and rehybridized with 
GAPDH specific probes. 
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did not transactivate the promoter, both in the 
absence and presence of ATRA. To verify 
that RARα and RXR were expressed and 
functional, a control luciferase construct was 
used containing three bona-fide RAREs from 
the RARβ promoter (RARE3-tk-luc [39]). 
This construct was strongly transactivated in 
the presence of ATRA through endogenous 
retinoic acid receptors (Figure 2B, left bars). 
This was further enhanced when RARα and 
RXR were co-transfected (2B, right bars). 
Together this shows that PML-RARα may 
regulate ID1 expression through the upstream 
963 bp promoter whereas RARα/RXR 
cannot. 
To test whether PML-RARα expression 
would result in ATRA-dependent induction 
of the endogenous ID1 gene, we used the 
U937-PR9 cell line that is stably transfected 
with a Zn2+-inducible PML-RARα expression 
cassette [34]. In PML-RARα expressing U937 
cells, ATRA strongly induced ID1 expression 
(Figure 2C, right panel), in contrast to U937 
cells that did not express PML-RARα (2C, 
left panel).
Transactivation of the ID1 promoter 
is dependent on GC- and CCAAT box 
motifs
To determine the DNA sequences that are 
relevant for the observed PML-RARα-
dependent transactivation, we analyzed 
Figure 2. The ID1 promoter is transactivated 
by PML-RARα but not by RARα/RXR. (A) 
Hep3B cells were transfected with the 963bp 
ID1 promoter-luciferase reporter construct (ID1-
luc) together with a control vector expressing 
Renilla-luciferase. In addition, vectors coding 
for the various proteins indicated in the figure 
were transfected. Transactivation is expressed as 
arbitrary units and is corrected for transfection 
efficiency measured by Renilla luciferase. 
Background luminescence of the cells transfected 
with only the reporter construct without nuclear 
receptors and in the absence of ATRA was 
set at 1. Cells were cultured for 16 hrs 
without (white bars) and with ATRA (black 
bars). Mean values and standard deviations 
from three independent experiments +/- SD 
are shown. (B) To show transactivation by 
unrearranged retinoic acid receptors, cells 
were transfected with the RARE3-tk-luc 
vector, containing three bona-fide RAREs. Mean 
values of three independent experiments +/- SD 
are shown. (C) ID1 expression is increased by 
PML-RARα in the presence of ATRA. The zinc-
inducible PML-RARα cell line U937-PR9 was 
grown in the absence (left panel) or presence (right 
panel) of zinc for 16 hours. Cells were treated 
with ATRA and harvested at the indicated time 
points. Proteins were size-fractionated by SDS-
PAGE. Immunostaining was done with anti-ID1 
antibody. 
A B
C
ATRA (hrs)0      4      8    12
+ PML-RARĮ
-ID1
no PML-RARĮ
0      4      8    12
0
2
4
6
8
10
12
14
16
vec
tor
PM
L-R
AR
D
RA
RD
/RX
R
RA
RD RX
R
PM
L
Fo
ld
tra
ns
ac
tiv
at
io
n
of
  9
63
 b
p
ID
1-
lu
c
-ATRA
+ATRA
0
10
20
30
40
50
60
70
vec
tor
RA
RD
/RX
R
Fo
ld
tra
ns
ac
tiv
at
io
n
of
 R
A
R
E
3-
tk
-lu
c
-ATRA
+ATRA
II
38
the 963 bp upstream promoter construct of 
the ID1 gene further. The consensus RAR/
RXR binding sequence (RARE) consists 
of a repeated (A/G)G(T/G)TCA sequence 
that is separated by two or five base pairs. 
However, in the 963 bp ID1 promoter, no 
consensus RARE was found. As PML-
RARα may bind to a much wider variety of 
DNA sequences [25, 26], we made luciferase 
constructs with different promoter truncations. 
All the truncation mutants could still be 
transactivated by PML-RARα (Figure 3B), 
including the smallest, 121bp promoter 
construct. This construct does not contain 
any sequence that even remotely resembles 
a retinoic acid receptor-binding site (Figure 
3A). Analysis of the 121 bp promoter 
sequence for putative binding sites for 
other transcription factors showed a perfect 
consensus-binding site for the transcription 
factors NF-Y (CCAAT box), and Sp1 (GC 
box). To test their relevance, we mutated 
these sites individually and in combination in 
the context of the 963 bp promoter fragment. 
Mutation of the GC box or the CCAAT box 
alone partially impaired transactivation by 
PML-RARα, while deletion of the GC box 
and the CCAAT box in combination almost 
completely abolished transactivation (Figure 
3C, raw Renilla and Firefly luciferase data are 
Figure 3. The CCAAT- and GC-box in the 
ID1 promoter are required for PML-RARα 
mediated transactivation. (A) ID1 promoter 
region showing the presence of consensus Sp1 
and NF-Y binding sites. (B) Transactivation of ID1 
promoter-luciferase constructs. Several deletion 
constructs were generated and transfected in 
combination with RARα plus RXR, or with PML-
RARα. Transactivation assays were performed 
as described in figure 2. Mean values from three 
independent experiments +/- SD are shown. (C) 
To investigate the importance of the putative 
Sp1 and NF-Y binding sites in the -121 bp 
upstream promoter sequence of the ID1 gene for 
transactivation by PML-RARα, these sites were 
mutated in the context of the –963 bp promoter 
fragment. Mutations were introduced either alone, 
or in combination. Transactivation by PML-RARα 
was performed as described in figure 1. Sequences 
were mutated as follows; GC box: CCGCCC 
was replaced by CTATCC and for the NF-Y site: 
ATTGG was replaced by ACACG.
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given in supplemental figure 1, showing that 
normalization using Renilla did not change the 
results in a qualitative manner). This indicated 
that transactivation of the ID1 promoter by 
PML-RARα was dependent on the GC and 
CCAAT motifs.
Functional  NF-Y is  necessary for 
transactivation of the ID1 promoter by 
PML-RARα
Sp1 and NF-Y are ubiquitously expressed 
transcription factors. NF-Y is a trimeric 
protein complex consisting of the subunits 
NF-YA, NF-YB and NF-YC. All three 
subunits are necessary for the complex to 
bind to the DNA [40]. Using real-time PCR, 
we confirmed that Sp1 and all three NF-Y 
subunits were expressed in primary APL cells 
(supplemental figure 2). Binding of Sp1 to 
the promoter of ID1 was shown previously 
[41]. Therefore, we tested whether NF-Y 
was able to bind to the CCAAT site from the 
ID1 promoter. Incubation of a radioactively 
labeled DNA-probe containing the CCAAT 
box with cellular protein extracts resulted 
in a clear shifted complex (Figure 4A, lane 
1). This shift was competed by a 100-fold 
excess of non-labeled probe (lane 2) and by 
an excess of an oligo containing the NF-Y 
binding site of the CD10 promoter (lane 5 
[42]), but not by an excess of probe lacking a 
NF-Y binding site (lane 3). When anti-NF-YB 
antiserum was added (lane 4) the protein-
DNA complex was supershifted, identifying 
the DNA binding protein complex as NF-Y. 
To further test whether NF-Y is present on 
the endogenous ID1 promoter, we performed 
chromatin immunoprecipitation (ChIP) 
assays. Using anti-NF-YA antibody, recovery 
of the ID1 promoter sequences from U937 
cells was over 70 times higher than recovery 
with non-specific IgGs (Figure 4B, right bars). 
In the same experiment, no enrichment was 
seen for the RARβ promoter (Fig. 4B, left 
bars), indicating that NF-Y is present on the 
endogenous ID1 promoter but not on the 
RARβ promoter. 
A dominant-negative form of NF-YA (YAm29) 
has been described [43]. This mutated NF-YA 
subunit can still bind to the NF-YB and NF-
YC subunits, but is not able to bind to DNA, 
preventing the formation of a functional 
trimeric NF-Y complex. To investigate 
whether functional NF-Y was necessary 
for the transactivation of ID1, the YAm29 
mutant was tested in a transactivation assay. 
Transactivation of ID1 by PML-RARα upon 
ATRA treatment was severely decreased in 
the presence of dominant-negative NF-YA 
(Figure 4C). This effect was promoter-specific 
as YAm29 did not influence transactivation 
of the RARβ promoter construct (RARE3-
tk-luc) by PML-RARα or RARα/RXR (data 
not shown).
Upregulation of ID1 is dependent on PML-
RARα, but does not require the DNA-
binding domain of the fusion protein
To tes t  whether  PML-RARα  might 
transactivate the ID1 promoter without 
directly binding to the DNA, we used a 
PML-RARα construct from which the DNA 
binding domain was deleted (PML-RAR/∆R, 
[34]. PML-RAR/∆R has been shown to be 
unable to transactivate a promoter containing 
a bona-fide RARE. In contrast, PML-RAR/∆R 
retained the ability to transactivate the ID1 
promoter (Figure 4D). This indicated that 
transactivation of the ID1 promoter by PML-
RARα does not require direct binding of 
PML-RARα to the DNA. 
PLZF-RARα is generated by a t(11;17) 
translocation that is found in approximately 
2% of the patients with APL. It contains the 
same part of the retinoic acid-receptor as 
PML-RARα. Similar to PML-RARα, this 
fusion protein may form homodimers with 
DNA-binding capacity [44]. Interestingly, 
PLZF-RARα was not able to transactivate the 
ID1 promoter, suggesting that the PML part of 
PML-RARα is necessary for transactivation 
of the ID1 promoter (Figure 4D). When 
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Figure 4. NF-Y binds to the CCAAT-box element 
from the ID1 promoter, and is required for 
PML-RARα mediated transactivation. (A) 
EMSA showing binding of NF-Y to the putative 
NF-Y binding site from the ID1 promoter. Hep3B-
nuclear extracts were incubated with a labeled 
DNA probe containing the NF-Y-box from the 
ID1 promoter region. A clearly shifted protein-
DNA complex was seen (lane 1). Competition 
experiments were done with 100x cold ID1 probe 
(lane 2) and with an unlabeled probe containing the 
confirmed NF-Y binding site from the CD10 gene 
promoter (lane 5). In addition, a sequence without 
any recognizable NF-Y binding site was used for 
competition (lane 3). Addition of anti-NF-YB 
antibody shifted the complex to a higher molecular 
weight complex (lane 4). Arrows indicate free 
probe (1), shifted DNA-protein complex (2) and 
the supershifted DNA-protein-antibody complex 
(3). (B) To detect DNA-binding of NF-Y in intact 
cells, ChIP assays were performed using anti 
NF-YA antibodies. As a control, the non-specific 
IgG fraction from human serum was used. The 
Y axis shows the recovery (%) of ID1 or RARβ 
sequences relative to the input in U937 cells, NF-
Y clearly bound to the ID1 promoter (right bars), 
but not to the RARβ gene (left bars). Mean values 
from three independent experiments +/- SD are 
shown. (C) To further show the importance of 
NF-Y for the PML-RARα mediated transcriptional 
activation of ID1, transfections (as described in 
figure 2) were performed using the dominant-
negative NF-YA subunit (Yam29) and the 963 
ID1 promoter construct. In the presence of YAm29 
PML-RARα mediated transcription was severely 
diminished (right bars). (D) To investigate the 
importance of different domains of PML-RARα, 
vectors encoding the DNA binding-defective 
PML-RARα∆R mutant, and a mutant lacking the 
coiled-coil protein-protein interaction domain of 
PML (PML-RARα∆CC) were used. In addition, 
a PLZF-RARα expression construct was used. 
Transfections were performed as in figure 2 using 
the 963 ID1 promoter construct, mean values of 
three independent experiments +/- SD are shown.
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the coiled-coil domain of PML-RARα was 
deleted (PML-RAR/∆CC [25, 34]) it was no 
longer able to transactivate the ID1 promoter 
(Figure 4D). As this domain is involved in 
protein-protein interactions, this suggested 
that PML-RARα homodimerization or 
interaction of PML-RARα with another 
protein was necessary for the transactivation 
of ID1.
The ID2 promoter is also transactivated by 
PML-RARα but not by RARα/RXR
To investigate whether ID2 was regulated 
in a similar manner as ID1, we cloned the 
upstream promoter of ID2 (812bp) into a 
luciferase reporter plasmid. Similar to ID1, no 
consensus retinoic acid receptor-binding site 
could be found in the ID2 promoter sequence. 
Also comparable to ID1, RARα, RXR, 
PML, PLZF-RARα and RARα/RXR did 
not transactivate the ID2 promoter whereas 
PML-RARα did (Figure 5A). Furthermore, 
transactivation of ID2 by PML-RARα was 
abolished in the presence of dominant-
negative NF-YA (Figure 5B). Inspection of 
the ID2 promoter sequence revealed 3 NF-Y 
and 5 Sp1 consensus binding sites (Figure 
5C). Together, these data show that like ID1, 
ID2 may also be transactivated by PML-
RARα without direct DNA binding of the 
fusion protein. 
Figure 5. The ID2 promoter is transactivated 
by PML-RARα but not by RARα/RXR. (A) 
Cells were transiently transfected with a 812 
bp ID2-luciferase reporter construct (ID2-luc) 
. Transfections and controls were as described 
in figure 2. Background luminescence of the 
cells transfected with only a reporter construct 
(no nuclear receptor and no ATRA) was set at 
1. Transactivation was measured after treatment 
without (white bars) and with (black bars) 10-6M 
ATRA. Mean values from at least three independent 
experiments +/- SD are shown. (B) Dominant 
negative NF-Y (Yam29) inhibits the transactivation 
of the ID2 promoter construct by PML-RARα. 
Transfections were done as described in figure 2, 
mean values of three independent experiments +/- 
SD are shown. (C) Promoter region of the ID2 gene 
with putative Sp1 and NFY binding sites.
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PML-RARα directly interacts with Sp1 
NF-Y and Sp1 have been shown to work in 
concert on many promoters. Direct physical 
interaction between Sp1 and NF-Y has been 
shown, indicating that these proteins may 
bind to adjacent DNA binding sites and form 
a complex that regulates transcription [45]. 
We investigated whether PML-RARα could 
physically interact with Sp1 or NF-YA. GST-
tagged, bacterially produced NF-YA, and 
Sp1 proteins were made, as well as in vitro 
translated (reticulocyte lysate) PML-RARα 
for GST pull-down experiments. rhSp1 was 
commercially available. Whereas a clear 
interaction was observed between GST-NF-
YA and recombinant Sp1 (Figure 6A), in none 
of the conditions tested we could show a direct 
interaction between NF-YA and PML-RARα. 
In contrast, an interaction between PML-
RARα and Sp1 was readily observed, whereas 
no interaction was seen with non-loaded or 
GST-loaded beads (Figure 6A). GST-Sp1 
was also able to capture PML-RAR/∆CC 
although with a much lower efficiency than 
PML-RARα. This suggests that the binding of 
PML-RARα is partly through the coiled-coil 
Figure 6. PML-RARα binds Sp1 and binds to 
the endogenous ID1 promoter. (A) To test binding 
of PML-RARα to Sp1 and NF-Y, GST pull-down 
experiments were performed. Empty beads and 
beads loaded with GST or GST-NF-YA (panels to 
the left) were incubated with in vitro translated Sp1 
(positive control) or in vitro translated PML-RARα. 
GST-Sp1 (panels to the right) was incubated with in 
vitro translated PML-RARα or PML-RARα∆CC. 
Beads were washed and subsequently resuspended 
in loading buffer. Protein was resolved on SDS-
PAGE. Immunostaining was performed with anti-
Sp1 or anti-RARα antibody. Clear interactions 
between NF-YA and Sp1 and between PML-RARα 
and Sp1 were observed. To show binding of PML-
RARα to the endogenous RARβ (B) and ID1 (C) 
genes, ChIP assays were performed in PML-RARα 
positive NB4 cells and in PML-RARα negative 
U937 cells. Cells were treated with ATRA for 30 
min. ChIP was done with anti-PML antiserum. As 
a control, the non-specific IgG fraction from human 
serum was used. The Y axis shows the recovery 
(%) of ID1 or RARβ sequences relative to the 
input. Mean values of 4 independent experiments 
are shown. 
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region and partly through the RARα part of 
the fusion protein. This is in agreement with 
earlier publications that have shown binding 
of both PML and RARα to Sp1 [22, 23].
PML and PML-RARα are present on the 
endogenous ID1 promoter
To show the physical interaction of PML-
RARα with the endogenous ID1 and ID2 
promoters in intact cells, we performed 
ChIP assays using PML-specific antibodies. 
The RARβ promoter, that contains a well 
defined RARE, served as a positive control. 
In NB4 cells, we found a clear enrichment 
for the RARβ promoter (Figure 6B, right 
panel). In contrast, in U937 cells which are 
PML-RARα negative, no enrichment for the 
RARβ promoter was seen (6B, left panel), 
indicating that PML-RARα binds to the RARβ 
promoter in NB4 cells. The ID1 gene was also 
precipitated with anti-PML antibody in NB4 
cells (Figure 6C, right panel). However, this 
was not only observed in the PML-RARα 
positive NB4 cells, but also in the PML-
RARα negative U937 cells (Figure 6C, left 
panel). This indicates that in U937 cells, 
unrearranged PML protein was present on 
the ID1 promoter. As the anti-PML does not 
discriminate between PML and PML-RARα, 
we could not determine which of these two 
Figure 7. Binding of PML-RARα to the 
endogenous p21, RAR-β, ID1 and ID2 genes. 
To show binding of PML-RARα and NF-Y to the 
endogenous p21, RAR-β, ID1 and ID2 genes ChIP 
assays were performed. As anti-PML antibodies 
do not discriminate between the unrearranged 
PML protein and the PML-RARα fusion protein, 
FLAG-tagged PML-RARα was used. Cells were 
transfected with or without FLAG-PML-RARα and 
cultured in the presence or absence of 10-6 M ATRA. 
ChIP was performed using anti-FLAG-antibodies, 
anti-NF-YA antibodies and control IgGs. The Y axis 
shows the recovery (%) of ID1/ID2/p21 or RARβ 
sequences relative to the input. Mean values of 
three independent experiments +/- SD are shown. 
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Figure 8. PML-RARα transactivates the HES1 
promoter without direct DNA binding. (A) Total 
RNA samples derived from non-stimulated and 
ATRA-stimulated NB4 cells (10-6 M ATRA was 
added for indicated time intervals) were subjected 
to RT-PCR using specific primers for the detection 
of HES1 mRNA. (B) Total cell lysates (75 mg) 
from non-stimulated and ATRA-stimulated NB4 
cells (10-6 M ATRA was added for indicated time 
intervals) were subjected to immunoblot analysis 
using HES1 antibody. The same blot was reprobed 
with a β-actin antibody to demonstrate equal 
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loading. The molecular weight 
(kDa) marker is indicated at the 
left. (C,D,E) Hep3B cells were 
transfected with a HES1 promoter-
luciferase reporter construct 
(pGL3-HES1), a control vector 
expressing Renilla-luciferase and 
vectors coding for the various 
proteins indicated in the figure. 
Background luminescence of 
the cells transfected with only 
the reporter construct in the 
absence of ATRA was set to 1. 
Transactivation was corrected for 
transfection efficiency measured 
by Renilla activity. Cells were cultured with (black 
bars) or without (white bars) ATRA. Mean values 
and standard deviations from three independent 
experiments are shown. (F) ChIP assays were 
performed both for the HES1 promoter and for 
the RARβ promoter. Sonicated chromatin of HEK 
293 cells transfected with FLAG-PML-RARα or of 
non-transfected HEK 293 cells were used for ChIP 
analysis using antibodies against NF-YA or FLAG 
or non-specific IgG as a control (n=4). Where 
indicated, cells were cultured in the presence of 
ATRA. Quantitative PCR was used to measure the 
amount of immunoprecipitated DNA of the HES1 
and RARβ promoter, which was compared to the 
control genomic sequences of ALBUMIN. The 
recovery of HES1 and RARβ was plotted as the fold 
enrichment over the recovery of ALBUMIN.
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proteins was bound to the ID1 promoter in 
NB4 cells. To investigate this further we 
used a FLAG-tagged PML-RARα expression 
construct, allowing us to unequivocally 
identify binding by the PML-RARα fusion 
protein. HEK-293 cells were transfected 
with FLAG-PML-RARα (Figure 7A). As a 
negative control, ChIP was performed using 
non-specific IgGs. We compared the presence 
of (FLAG-tagged) PML-RARα and NF-Y on 
the two classical ATRA target genes RARβ 
and p21, and on ID1 and ID2. Enrichment of 
all 4 promoters was found using anti-FLAG 
antibody, indicating that PML-RARα was 
bound to these four genes in intact cells 
(Figure 7A, compare upper and middle rows). 
Using anti-NF-Y antibody, enrichment of 
the ID1 and ID2 promoters was found but 
no enrichment of RARβ and p21, indicating 
that NF-Y was present on ID1 and ID2, but 
not on the two classical ATRA target genes 
RARβ and p21. To see whether the presence 
of PML-RARα and NF-Y on the different 
promoters would be altered by the presence of 
retinoic acid, ChIP assays were performed in 
the presence and the absence of ATRA (Figure 
7, middle and bottom rows). ATRA did not 
influence the binding of NF-Y or PML-RARα 
to these promoters showing that their binding 
is ligand-independent.
HES1 is transactivated by PML-RARα in 
a similar manner as ID1 and ID2
Besides the ID proteins, Hairy-Enhancer of 
Split (HES) proteins (HES1-7) also act as 
transcriptional repressors of bHLH-regulated 
genes. Like ID proteins, HES proteins act, 
amongst other mechanisms, by sequestration 
of bHLH transcription factors into non-
functional heterodimeric complexes [46, 47]. 
Analysis of the HES1 promoter sequence 
revealed a perfect CCAAT- and GC-box 
within 100bp upstream of the TATA-box. To 
investigate whether, besides the ID proteins, 
other inhibitors of bHLH transcription factors 
are regulated in APL cells, we assessed the 
expression level of HES1 during ATRA-
induced granulocytic differentiation of APL 
cells. Total RNA and protein was isolated 
from the PML-RARα positive APL cell line 
NB4, cultured in the absence or presence of 
ATRA for several time intervals, and HES1 
expression levels were measured by RT-PCR 
(Figure 8A) and Western blotting (Figure 8B). 
HES1 mRNA and protein expression levels 
were induced within half an hour of ATRA 
stimulation and reached maximum levels at 1 
hour of ATRA stimulation. Subsequently, from 
1 to 24 hours following ATRA stimulation, 
HES1 mRNA expression levels decreased 
about 100-fold and remained at this level 
during further differentiation. HES1 protein 
levels diminished to undetectable levels at 4 
hours of ATRA stimulation. To investigated the 
mechanism that resulted in the transcriptional 
activation of HES1 by PML-RARα. We cloned 
a 283 bp fragment of the HES1 promoter, 
including the putative TATA-box, into a 
luciferase reporter construct. When expressed 
alone, RARα, RXR and PML were not able 
to transactivate this HES1 promoter construct 
both in the absence and presence of ATRA. 
The combination RARα/RXR also did not 
transactivate the promoter. In contrast, PML-
RARα transactivated the promoter more than 
6-fold in an ATRA-dependent fashion (Figure 
8c). Similar to the ID1 and ID2 promoters, 
PML-RARα∆R did, and PML-RARα∆CC and 
PLZF-RARα did not transactivate the HES1 
promoter (Figure 8d). Transactivation of 
HES1 by PML-RARα was strongly decreased 
in the presence of dominant-negative NF-YA 
(Figure 8E). This indicates that PML-RARα-
dependent transactivation of the HES1 
promoter is also dependent on a functional 
NF-Y complex. ChIP assays using chromatin 
from PML-RARα transfected cells revealed 
a clear increase in HES1 promoter recovery 
when compared to untransfected cells, 
indicating that PML-RARα is present on the 
HES1 promoter (Figure 8F). The ChIP assays 
also revealed the presence of NF-Y on the 
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HES1 promoter. We conclude that the HES1 
promoter is regulated in a similar manner as 
the ID1 and ID2 promoters.
Together, these data show that there are two 
different mechanisms by which PML-RARα 
may regulate the transcription of target genes 
(Figure 9). The first class of target genes 
consists of genes that contain a retinoic acid 
response element in their promoter. These 
genes are normally regulated by unrearranged 
retinoic acid receptors and may be deregulated 
by PML-RARα in a dominant-negative 
manner in the absence of ligand. In the 
presence of high concentrations of ligand, 
their expression is restored. The second class 
of target genes consists of genes that are not 
normally regulated by retinoic acid receptors. 
Fusion of the RARα moiety to PML renders 
these genes responsive to retinoic acid, which 
defines a novel gain-of-function for the PML-
RARα fusion protein.
Discussion
The successful treatment of APL with 
high dose retinoic acid has shown that 
the differentiation block of the malignant 
cells can be overcome, leading to terminal 
differentiation of the leukemic cells and 
disappearance of the disease. As this is one of 
the first examples of successful differentiation-
induction therapy in cancer, many studies 
focused on the molecular mechanisms that 
contribute to the transformation to leukemia, 
and on the mechanisms that mediate the 
retinoic acid-induced differentiation of the 
cells. PML-RARα was shown to interfere 
with the expression of normal RARα target 
genes. RARα is an important modulator 
of granulopoiesis and acts either by direct 
binding to the DNA, or through interaction 
with other transcription factors. In this report 
we show that PML-RARα interacts with 
Sp1 and may interfere with the expression 
of genes that are not normally regulated by 
retinoic acid receptors. Previously, it was 
shown that both unrearranged PML [48] and 
unrearranged RAR/RXR complexes [22, 23] 
are able to interact with Sp1. Therefore, the 
interaction of PML-RARα with Sp1 could 
be mediated by the RARα part as well as 
the PML part of the fusion protein. Here we 
show that PML-RARα binds Sp1 and that this 
binding is less efficient when the coiled-coil 
domain is deleted. The lack of response of the 
ID1 and the ID2 promoters to RARα/RXR, 
PLZF-RARα and PML-RAR/∆CC (Figures 
2 and 5) suggests that the PML part of the 
fusion protein is essential for regulating 
transcription.
We show that PML-RARα physically 
interacts with Sp1 in the absence of DNA 
Figure 9. Dominant negative and gain-of-
function model for PML-RARα. (1) Genes that 
are regulated through a retinoic acid responsive 
element (RARE) may be bound by PML-RARα. 
Competition with normal, unrearranged retinoid 
receptors results in a dominant-negative silencing 
of the gene by PML-RARα in the absence of ligand. 
Addition of high dose retinoic acid may reverse the 
silencing, allowing transcription. (2) Sp1 and NFY 
regulated genes may be targeted by PML-RARα 
through interaction with Sp1. Tethering of PML-
RARα to these promoters renders them responsive 
to retinoic acid, representing a gain-of-function for 
the PML-RARα fusion protein. 
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(Figure 6). Roder et al. have shown that 
NF-Y and Sp1 interact physically in the 
absence of DNA. This suggests that the PML-
RARα/Sp1/NF-Y complex may form before 
binding to DNA. Figure 3C suggests that the 
PML-RARα/Sp1/NF-Y complex still binds, 
although less efficiently, to the ID1 promoter 
when one transcription factor binding site is 
mutated. Figure 4C shows that the presence of 
a dominant negative form of NF-Y abolishes 
transactivation of the ID1 promoter by PML-
RARα. We hypothezise that this dominant 
negative form of NF-Y disrupts the PML-
RARα/Sp1/NF-Y complex and thereby 
impairs binding to and transativation of the 
ID1 promoter.  We propose a model in which 
PML-RARα binds to a DNA-bound Sp1-NF-
Y complex, rendering the expression of these 
genes sensitive to ATRA, and defining a novel 
gain-of-function for the fusion protein (Figure 
7B). In the ChIP experiments, we show that 
unrearranged PML is recruited to the ID1 gene 
(Figure 6C). The physiological meaning of 
this remains unclear as no effect of PML was 
observed in the transactivation assays. 
As Sp1 is involved in the transcriptional 
control of various myeloid-specific genes 
[49, 50] deregulation of its target genes may 
be relevant in APL. For ID1 and ID2, a role 
in myelopoiesis and in APL was described 
previously. Overexpression of ID1 or ID2 
in NB4 cells inhibits their proliferation and 
induces a G0/G1 arrest [31]. In addition, 
ectopic expression of ID1 in CD34+ cells 
inhibited eosinophil development, whereas 
neutrophilic differentiation was enhanced. 
Expression of ID2 accelerated the definitive 
maturation of myeloid cells [51]. Other genes 
may be targeted by a similar mechanism as 
well. Overexpression of both ID1, ID2 and 
HES1 may reveal whether simultaneous 
inhibition of a wider range of HLH factors 
may have an even more profound effect on 
differentiation. 
The promoter of the important retinoic acid 
responsive gene C/EBPβ was transactivated 
by PML-RARα, but also lacks a consensus 
RARE within the tested region [52, 53]. 
Possibly, also this gene is (de)regulated by 
tethering of PML-RARα to the promoter 
through protein-protein interactions rather 
than by direct DNA-binding.
Apart from the DNA-binding domain from 
RARα, the coiled-coil domain of PML was 
shown to be important for optimal induction of 
terminal differentiation by the fusion protein 
[54]. This suggested that homodimerization 
of PML-RARα is an important feature of the 
fusion protein, but might also indicate that 
other protein-protein interactions mediated 
through the PML part are involved. Several 
alternative RARα fusion proteins occur at 
low frequency (2% of the cases) in APL 
patients, in which the same part of RARα is 
fused to other proteins than PML (reviewed in 
[44]). Common to the various RARα partner 
proteins is the presence of a dimerization 
domain, suggesting that homodimerization 
is an important property of these fusion 
proteins. However, depending on the fusion 
partner, the sensitivity to retinoic acid differs 
suggesting a broader role for the RARα 
partner protein than just the provision of a 
dimerization domain. Specifically, PLZF-
RARα positive leukemia appears to be more 
resistant to ATRA, which has been explained 
by the recruitment of corepressors by the 
PLZF-part of the fusion protein that are not 
released upon treatment with ATRA [15, 
55]. This insensitivity could be reversed, as 
treatment with a combination of ATRA and 
G-CSF induced granulocytic differentiation in 
a synergistic manner [56]. Also in transgenic 
mice, different types of disease with different 
sensitivities to ATRA developed for the 
various fusion proteins [7, 30]. Furthermore, 
when RARα fusion proteins were made by the 
coupling of RARα to artificial dimerization 
domains, several characteristics of PML-
RARα were recapitulated in vitro, but in vivo 
these proteins induced leukemia with very 
low efficiency [57]. Interestingly, when these 
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fusion proteins were expressed in a PML -/- 
background, the animals did still not develop 
leukemia efficiently, leading to the conclusion 
that the mere combination of disruption of 
PML and dimerization of RARα does not 
recapitulate the full oncogenic potential of 
PML-RARα, and that the fusion protein has 
gain-of-function characteristics. Together, 
this showed that dimerization of RARα is 
important but not sufficient to reproduce the 
complete phenotype of PML-RARα. 
It remains to be investigated whether PML-
RARα recruits co-repressors to the promoters 
of Sp1 and NF-Y target genes. This would 
lead to repression of gene expression in the 
absence of ATRA, possibly contributing to 
transformation of the cells, similar to the 
effect of PML-RARα on regular retinoic 
acid receptor target genes. So far, we did not 
observe important downregulation of ID1 and 
ID2 mRNA in freshly isolated leukemia cells 
from APL patient cells compared to non-APL 
acute myeloid leukemia cells, suggesting 
that this is not the case (data not shown). 
However, as ID1 and ID2 expression in most 
leukemic samples was low, further studies 
are required. 
Additionally, we do not exclude the presence 
of RXR in the PML-RARα/Sp1/NF-Y 
complex. RXR is an essential part of the 
PML-RARα complex during transformation 
and synergy has been shown between ATRA 
and RXR specific agonist on transctiptional 
activation (Zhu et al 2007, Perez et al. 
Kamashev et al Jansen et al.). Therefore, RXR 
specific agonist may also effect transcription 
of Sp1 and NF-Y target genes.  
In summary, we define a novel, Sp1 and 
NF-Y-dependent mechanism by which the 
PML-RARα fusion protein interferes with 
gene transcription. This implicates that 
PML-RARα (de)regulates an additional 
class of genes that are normally not regulated 
by retinoid receptors and defines a gain-of-
function for the PML-RARα fusion protein.
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Supplemental figure 1. Transactivation data before correction. Raw luciferase activaties are 
shown for one transactivation experiment from figure 3C. The ID1 promoter, wt or with a mutated 
GCbox and/or CCAATbox, was cloned in front of the firefly gene. A renilla Expression construct 
was co-transfected for correction. Note that the correction does not qualitivily change the results.
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Supplemental figure 2. NF-Y and Sp1 are 
expressed in APL cells. MRNA expression levels 
of NF-YA (A) and Sp1 (B) were determined 
in mononuclear cells from 3 APL patients. 
Bone marrow samples were obtained from 
t(15;17) APL patients following informed consent. 
Mononuclear cells were isolated by density 
gradient centrifugation using ficoll (1.077 g/ml, 
Sigma). Cells were taken up in RNA-bee (ISO-
TEX Diagnostics, Friendswood, USA). RNA was 
used as template in a RT-DNA reaction as described 
before (de vries br j cancer 1999). Quantitative 
PCR was performed with the ABI/PRISM 7700 
Sequence Detection system (ABI/PE, Foster City, 
Ca, USA). As a reference gene we used PBGD 
(de vries br j cancer 1999). The primer/probe sets 
for detecting NF-YA and Sp1 were from Applied 
biosystems (Foster City, Ca, USA). PCRs were 
performed in universal master mix (Roche).
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The PML-RARα fusion protein 
enhances MDM2 protein levels
Abstract
APL is characterized by the PML-RARα fusion protein. We investigated the effect of 
PML-RARα on MDM2 expression. Ectopic expression of PML-RARα increased MDM2 
protein levels. Degradation of PML-RARα correlated with downmodulation of MDM2. 
As PML-RARα may inhibit p53 function by enhancing MDM2 levels we tested whether 
MDM2 inhibition would trigger apoptosis. Treatment of leukemia cells with the MDM2 
antagonist Nutlin-3 resulted in induction of apoptosis. We conclude that PML-RARα 
may contribute to leukemogenesis by enhancing MDM2 protein levels which results in 
inactivation of p53. Targeting MDM2-mediated inactivation of p53 could be a potential 
option to treat retinoic acid resistant APL.
Introduction
Disruption of p53 function is a common trait 
of malignant cells, and TP53 is presently 
considered to be the most frequently mutated 
gene in human cancer [1]. In leukemia, 
mutations in the TP53 gene are less frequent, 
occurring in approximately 10% of the cases 
[2]. Therefore, it has been suggested that in 
hematological malignancies the function of 
p53 is deregulated by other mechanisms. One 
of the most important negative regulators of 
p53 is MDM2. MDM2 binds to p53, blocks 
p53-mediated transactivation and targets p53 
for proteasomal degradation [1]. In leukemia, 
mdm2 gene amplification was not found, 
but overexpression of MDM2 mRNA may 
occur in up to 50% of the cases [3]. Apart 
from deregulated mRNA expression, altered 
MDM2 function may occur in leukemia by 
other means. 
Another regulator of p53 function is p14arf. 
p14arf induces the p53 pathway by inhibiting 
the activity of MDM2. We have shown 
that the transcription of p14arf is directly 
repressed by the AML1-ETO fusion gene [4], 
suggesting a direct link between the t(8;21) 
specific oncogene and deregulation of the 
p53 pathway.
Here we study MDM2 in acute promyelocytic 
leukemia (APL). APL is characterized by the 
PML-RARα fusion protein which usually 
results from a reciprocal t(15;17) chromosome 
translocation [5]. Earlier, it was shown that 
the wild type PML protein regulates the p53 
pathway at several levels. Wild type PML 
localizes to the multiprotein nuclear sub-
structures termed nuclear bodies. P53 protein 
is recruited to these nuclear bodies by PML 
upon oncogenic stress, where p53 is activated 
by acetylation by CBP/p300. In addition, 
binding of PML to p53 antagonizes the binding 
of MDM2, thereby stabilizing the p53 protein. 
Finally, PML is able to sequester MDM2 
to the nucleolus, resulting in diminished 
p53 degradation [6]. PML-RARα does not 
bind p53 because of loss of the carboxy-
terminus of PML in the fusion protein. PML-
RARα expression does however impair p53 
activation and triggers p53 degradation. This 
process is dependent on several factors. Wild 
type PML protein needs to be present as a 
bridging factor between PML-RARα and p53. 
PML-RARα needs to recruit HDAC activity 
which is dependent on a domain in the RARα 
part of the fusion protein. Finally, proteasomal 
degradation is dependent on the presence of 
MDM2 [7]. Expression of the PML-RARα 
fusion protein causes deacetylation of p53, 
resulting in repression of transcriptional 
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activity, and MDM2-dependent degradation 
of p53 [7]. However, the effect of PML-RARα 
on MDM2 is unknown.
Materials and Methods
Reagents
The selective MDM2 antagonist, Nutlin-3 
(racemic, EMD Biosciences, San Diego, CA), 
was dissolved in ethanol (10 mM) and was 
stored at -20ºC. ATRA (Sigma, St Louis, MO) 
was used at 10-6 M, ZnSO4 at 100 µM..
Cell lines and APL samples 
NB4 cells and U937-pr9 cells (kindly provided 
by Dr. P.G. Pelicci) were cultured in RPMI 
1640 medium (Gibco, Gaithersburg, MD) 
supplemented with 10% FCS (Gibco). Bone 
marrow samples were obtained from t(15;17) 
APL patients following informed consent. 
Mononuclear cells were isolated by density 
gradient centrifugation using ficoll (1.077 
g/ml, Sigma). The percentage of APL cells 
was determined by staining for PML-RARα 
microspeckles [5] using anti-PML (PG-M3, 
Santa Cruz, CA) and was in all cases > 80%. 
Cells were cultured in RPMI 1640 medium 
supplemented with 20% FCS.
Quantitative PCR
RNA was isolated using RNAzol (Campro 
Scientific, Veenendal, the Netherlands) 
according to the manufacturer’s instructions. 
For cDNA synthesis, 1 µg total RNA 
was reverse-transcribed using random 
hexanucleotide primers. Quantitative PCR 
was performed with the ABI/PRISM 7700 
Sequence Detection system (ABI/PE, Foster 
City, Ca, USA) using Sybr Green PCR 
(Applied Biosystems). As a reference, 
expression of the PBGD was measured [8]. 
The primers for detecting p14arf were forward: 
5’-AGCAGCCGCTTCCTAGAAGAC, 
reverse 5’-CACGGGTCGGGTGAGAGT. 
Primers for detecting MDM2 were: forward 
5’-ACCACCTCACAGATTCCAGCTT, 
reverse 5’-GCACCAACAGACTTTAATAA
CTTCAAA.
Cell proliferation and apoptosis analysis
Cells were washed with HBSS and incubated 
in 100 μL annexin V buffer (10mM HEPES, 
140 mM NaCl and 2.5 mM CaCl2, pH 7.4) 
with 5 μL annexin V (Molecular Probes, 
Figure 1. PML-RARα induces MDM2 protein 
levels and not mRNA levels. (A) U937-pr9 cells 
were treated with Zn2+ to induce PML-RARα 
expression. Cells were harvested 0 and 24 hours 
after Zn2+ treatment. Using quantitative PCR 
MDM2 mRNA levels, relative to PBGD mRNA 
levels, were determined. ATRA was used at 
10-6 M, ZnSO4 at 100 µM. (B) U937-pr9 cells 
were treated with Zn2+ to induce PML-RARα 
expression. Cells were harvested after the indicated 
period of time in SDS-loading buffer. Protein was 
resolved on SDS-PAGE. Immunostaining was 
done with MDM2 and β-actin specific antibody.
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Figure 2.  ATRA treatment of APL cell 
line NB4 results in downregulation 
of MDM2 protein. NB4 cells were 
treated with ATRA to induce terminal 
differentiation and degradation of PML-
RARα. Cells were harvested after the 
indicated period of time in SDS-loading 
buffer. Protein was resolved on SDS-
PAGE. Immunostaining was done with 
MDM2 and β-actin specific antibody. 
Leiden, the Netherlands). After 30 min. 
another 400 μL of annexin V buffer and 
propidium iodide (PI, 25 µg/ml) was added. 
Samples were analysed on a flow cytometer 
(Beckman coulter).
Western blot analysis.
For Western blot, cells were FACS-sorted 
and directly taken up in sample buffer 
(0.125 M Tris-HCL (pH 6,8), 1% SDS, 5% 
2-mercaptoethanol, 5% glycerol). Extracts 
were separated on a 10% SDS-polyacrylamide 
gel, and transferred to a PVDF membrane. 
MDM2 was visualised using specific antibody 
(SMP14, Santa Cruz, CA).
Results and discussion 
To study the effect of the PML-RARα fusion 
protein on MDM2 expression we used the 
U937-pr9 cell line that harbors a Zinc-
inducible PML-RARα expression cassette 
[9].  First, we confirmed the induction of 
PML-RARα in these cells by zinc. The PML 
protein is normally localised to large nuclear 
bodies and is delocalised, in the presence of 
the PML-RARα fusion protein, to multiple 
small dots, termed microspeckles [5]. Twelve 
hours after addition of zinc to the culture 
medium, the appearance of microspeckles 
was seen in the cells (data not shown). Using 
quantitative PCR, we analysed the amount of 
MDM2 mRNA , relative to the control gene 
PBGD. No up- or downregulation of MDM2 
mRNA levels was found upon the expression 
of PML-RARα (Figure 1A). In contrast, the 
induction of PML-RARα resulted in a clear 
upregulation of the p60 form of MDM2 protein 
(Figure 1B). The p60 protein is an isoform of 
MDM2 that is produced by caspase cleavage 
of the full length MDM2 protein [10]. When 
APL cells are treated with all-trans retinoic 
acid (ATRA), the cells differentiate towards 
mature granulocytes, which is accompanied 
by degradation of the PML-RARα fusion 
protein [11]. Therefore, we studied the level 
of MDM2 protein expression in NB4 cells 
before and after stimulation with ATRA. The 
p60 form of MDM2 was clearly detectable 
in untreated NB4 cells (Figure 2). Treatment 
with ATRA resulted in a clear downregulation 
of MDM2 p60 protein levels (Figure 2). As 
PML-RARα expression had no effect on 
MDM2 mRNA levels, this suggests that PML-
RARα expression results in increased MDM2 
p60 protein levels through a transcription 
independent process. High expression levels 
of the p60 form of MDM2 have been shown 
to inhibit p53 transcriptional activity [12]. 
The p60 form of MDM2 has lost its carboxy-
terminal domain, which contains the RING 
domain necessary for ubiquitination of p53. 
However the p60 form of MDM2 retains 
its domains to bind p300 and p53. So, p53 
acetylation in APL cells may be impaired 
both by HDAC recruitment by PML-RARα 
and high levels of MDM2 p60 protein. The 
p60 form of MDM2 has been found in several 
tumor cell lines, and in breast tumors [10]. 
Therefore, tumor cells overexpressing the 
p60 form of MDM2 may be protected from 
p53-mediated apoptosis.
To study whether upregulation of MDM2 
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by PML-RARα is functionally important 
in APL cells, we used Nutlin-3. Nutlins are 
a novel class of synthetic small molecules, 
which disrupt the binding of MDM2 to 
p53, thereby inhibiting p53 degradation 
and activating p53-dependent apoptotic 
pathways [13]. The relevance of this finding 
was recently underscored by the fact that 
restoring endogenous p53 expression in 
murine lymphomas, sarcomas and liver 
carcinomas resulted in tumor regression 
while not affecting normal tissues. This 
indicates that these tumors rely on sustained 
p53 inactivation for their growth and that 
reactivation of p53 function is a potential 
avenue for therapeutic development [14]. 
In both the U937 and NB4 cell lines, p53 is not 
functional [7]. Therefore, we tested the effect 
of Nutlin-3 on freshly isolated leukemia cells 
from APL patients (>80% pure).  Apoptosis 
was determined by staining for Annexin V 
and PI. After one day of culture, cells were 
exposed to Nutlin-3 or vehicle control. When 
cells were treated with 0, 1, 5 and 12.5 µM 
of Nutlin-3, a time- and dose-dependent 
increase in apoptosis was observed (Figure 
3A).  Subsequently, we tested leukemic cells 
from five different APL patients using 5 µM 
of Nutlin-3 (Figure 3B). In four patients, 
a clear increase in apoptosis was observed 
within 48 hours. In one patient, no significant 
effect of Nutlin-3 was seen. The APL cell line 
NB4, which contains a mutated p53 gene, was 
insensitive to Nutlin-3. This data indicates 
that inhibition of MDM2 in APL cells may 
activate the p53-apoptotic pathway. Earlier, 
Kojima et al. [15] showed that Nutlin-3 
induces p53-dependent apoptosis in non-APL, 
acute myeloid leukemia (AML) cells that do 
not carry TP53 mutations. In addition, they 
showed that the leukemic cells were more 
sensitive to this compound than normal CD34+ 
colony forming cells. This indicates a broad 
applicability of Nutlins in the treatment of 
leukemia. The sensitivity to Nutlins suggests 
that in many AML patients, p53 remains 
functional, but that the p53 pathway is 
defective, upstream of p53. 
How PML-RARα enhances MDM2 protein 
levels remains unclear. In PML-RARα positive 
cells PML localises into microspeckles 
instead of into normal PML nuclear bodies. 
We hypothesise that, since PML is able to 
bind MDM2 and sequester MDM2 to the 
nucleolus, MDM2 stabilization is due to 
a loss of function of PML in PML-RARα 
positive cells. In summary, we show that 
MDM2 proteins levels are upregulated by 
PML-RARα. As the functional antagonist 
of MDM2 (Nutlin-3) induces p53-dependent 
apoptosis in these cells, this suggests that 
enhancing MDM2 protein levels by PML-
RARα is an important property of the fusion 
protein that may contribute to the malignant 
transformation of the cells.
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Figure 3. MDM2 antagonists induce apoptosis 
in APL patient cells. Primary APL cells from 
patients were treated with the MDM2 antagonist 
Nutlin-3 or vehicle control. Bone marrow samples 
were obtained from t(15;17) APL patients. 
Mononuclear cells were isolated by density gradient 
centrifugation using ficoll (1.077 g/ml, Sigma). The 
percentage of APL cells was determined by staining 
for PML-microspeckles and was in all cases > 
80%. Cells were cultured in RPMI 1640 medium 
supplemented with 20% FCS for the indicated 
period. Nutlin-3 or vehicle control was added to 
the medium. Cells were harvested and washed with 
HBSS and incubated with annexin V and propidium 
iodide. Samples were analysed on a flow cytometer 
(A) APL cells from one patient were treated with 
different concentrations of Nutlin-3. (B) Primary 
APL cells from 5 different patients and NB4 cells 
were treated with the MDM2 antagonist Nutlin-3 
or vehicle control. After 0, 24 and 48 hours cells 
were analysed by flow cyometry. 
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The transcription factor NF-Y regulates 
the proliferation of myeloid progenitor cells
Abstract
The transcription factor NF-Y regulates the expression of several hematopoietic genes. To 
determine the biological role of NF-Y in hematopoiesis we expressed a dominant negative 
form of NF-Y in murine bone marrow cells by retroviral transduction. Inhibition of NF-Y 
function resulted in a significant reduction of granulocytic (CFU-G) and monocytic (CFU-
M) colony formation by 70% and 44 %, respectively. To study this reduction in more 
detail, we analysed the effect of dominant negative NF-Y on proliferation, differentiation 
and apoptosis. In more mature, MAC-1 positive cells, no differences in proliferation, 
differentiation and apoptosis were observed between dominant negative NF-Y- and vector- 
transduced cells. In contrast, the expansion of MAC-1 negative cells was completely 
abrogated by the expression of dominant negative NF-Y. Moreover, the inhibition of 
NF-Y function resulted in a significant increase in apoptosis in MAC-1 negative cells. 
Competitive transplantation of BM cells to irradiated mice, showed a repopulation 
advantage of vector-transduced cells versus dominant negative NF-Y transduced cells. 
Our data show that NF-Y regulates the proliferation of myeloid progenitor cells.
Introduction
During hematopoiesis, different maturation 
stages are defined by the expression of 
different sets of genes, a process regulated 
by specific transcription factors. Transcription 
factors that are essential for the outgrowth of 
pluripotent stem cells have been identified, 
such as AML-1 and SCL 1. Other transcription 
factors were shown to be essential for more 
lineage restricted progenitors cells. For 
example, C/EBPα for granulocytic cells 2. 
Mutations in various of these transcription 
factors are recurrently found in leukemia 1.
Recent studies have shown that the transcription 
factor, Nuclear Factor Y (NF-Y), regulates the 
expression of several hematopoietic (stem) 
cell genes. NF-Y regulates CD34 3, the 
human telomerase RNA gene 4 and HOXB4 
expression 5. HOXB4 expression increases 
stem cell expansion 6. Other known targets of 
NF-Y are cell cycle related genes, like Cyclin 
B1 which is involved in the G2/M transition. 
Using chromatin immunoprecipitation, NF-Y 
was shown to bind to the cyclin B1 promoter 
7. Upon p53-dependent G2-arrest, NF-Y 
mediates the inhibition of Cyclin B1 and B2 
promoters 8-10.
NF-Y was identified as a protein that binds 
a conserved element in the MHC class 2 
promoter called the Y box 1;11. NF-Y binds to 
a CCAAT box enhancer element, consisting 
of the consensus G/A, G/A, CCAAT, C/G, 
A/G, G/C sequence 12. NF-Y consists of three 
subunits NF-YA, -B and -C, and this trimeric 
complex is able to bind to the DNA and to the 
basal transcription machinery through binding 
of the TATA box-binding protein, TBP 13-15.
Deletion of both NF-YA alleles in mice, 
results in an incomplete and inactive NF-
Y complex, causing embryonic lethality. 
Inactivation of NF-YA in mouse embryonic 
fibroblasts results in a block in proliferation, 
which is followed by apoptosis 16. A few 
studies have been performed addressing the 
role of NF-Y in hematopoiesis. Mouse  bone 
marrow (BM) cells overexpressing NF-YA are 
biased towards primitive hematopoiesis and 
show increased repopulating ability after bone 
marrow transplantation 17. During macrophage 
differentiation NF-Y shows increasing binding 
activity to several promoters 18 and NF-Y has 
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been shown to mediate the IL-6 response 
in BM cells, which results in induction of 
macrophage differentiation 19. We used a 
dominant negative form of NF-Y (YAm29) 
20 to more precisely define the role of NF-Y 
in myelopoiesis.
Materials and Methods
DNA constructs 
The dominant negative form of NF-YA 
(YAm29) in pSG5 was a generous gift from 
Dr. Mantovani 20. pSG5-YAm29 was used 
as a template in a PCR reaction. Primers 
specific for NF-YA contained EcoR1 and 
Xho1 restriction sides. YAm29 was cloned in 
the retroviral vector pLZRS 21;22 using EcoR1-
Xho1, leading to the following sequence of 
viral DNA: LTR-YAm29-IRES-GFP-LTR. 
Transduction of murine bone marrow cells 
Chemicals and cytokines were from Sigma 
(Zwijndrecht, the Netherlands) unless stated 
otherwise. Bone marrow was harvested from 
6 weeks old, female CBA/CA mice. Cells 
were cultured for 2 days in pre-stimulation 
medium: IMDM medium (Invitrogen, Life 
Technologies, Breda, the Netherlands) 
supplemented with 10% FCS (Integro, 
Zaandam, the Netherlands), 1% penicillin and 
streptomycin solution; respectively 5000 units 
and 5mg/ml (Invitrogen), 7μl/l β-Mercapto-
ethanol, 1% BSA, 1% nucleoside mix (0.1mg/
ml cytidine, adenosine, uridine, guanosine, 
2’deoxycytidin, 2’deoxyadenosine, thymidine, 
2’deoxyguanosine), 10μg/mL bovine insulin 
(Invitrogen), 15μM chlorestorol, 15μM linolic 
acid, 0.62mg/mL human transferrin and the 
following recombinant cytokines: murine SCF 
50ng/mL, murine IL-12 10ng/mL, murine 
IL-3 10ng/mL, human Flt-3 50ng/mL, human 
TPO 10ng/mL (ITK Diagnostics, Uithoorn, 
the Netherlands), α-TGF-β 1µg/mL (ITK 
Diagnostics).
Cells were plated onto retronectin-coated 
culture dishes (Takara, Cambrex Bio science, 
Heerhugowaard, the Netherlands,) and 
exposed to the supernatant of packaging, 
ecotropic Phoenix cells, transfected with the 
indicated vectors. Supernatant was mixed 
(1/1) with 2*pre-stimulation medium.
Clonogenic and liquid culture assays 
24 hours after transfection BM cells were 
sorted for GFP positivity by FACS (Epics 
Elite, Beckman Coulter, Mijdrecht, the 
Netherlands). For the semi-solid culture 5000 
cells were plated per mL methylcellulose 
medium: 1.2% methylcellulose in IMDM 
medium supplemented with 0.1mL/mL 
Horse Serum, 0.1mL/mL Pokeweed Mitogen 
Stimulated Mouse Spleen Conditioned 
Medium (PWM, Invitrogen), 50ng/mL SCF, 
7μl/L β-mercapto-ethanol. Granulocyte 
colony-forming units (CFU-G) and monocyte 
colony-forming units (CFU-M) were counted 
5 days later using an inverted microscope. For 
the liquid cultures BM cells were grown in the 
same medium as used for the colony assays, 
but lacking methylcellulose. Cells were grown 
in 96 well plates.
Transplantation of murine bone marrow cells 
Transplantations were performed by injecting 
a 50/50 mixture of BM cells, transduced with 
YAm29 vector/empty vector, into irradiated 
mice (2 X 6 Gy at a 24 hours interval). For 
each transplantation, 0.25 X 106 sorted BM 
cells, transduced with YAm29, from C57BL6 
mice (CD45.2+) together with 0.25 X 106 
sorted BM cells, transduced with empty 
vector, from C57BL6 mice (CD45.1+) were 
used. Transplants were injected into the tail 
vein of recipients that were heterozygous 
for CD45.1 and CD45.2. Contribution from 
YAm29 and empty vector transduced cells 
were analysed 12 days after transplantation.
Differentiation analysis
For analysing the differentiation of the BM 
cells, cells were incubated with MAC-1 
specific antibody (1:100, Pharmingen, the 
Netherlands, Alphen a/d Rijn). Just before 
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FACS analysis 50μL of flow-check beads 
(Beckman coulter) was added to each sample 
to count the cells.
Western blot analysis 
For Western blot, cells were sorted and directly 
taken up in sample buffer (0.125 M Tris-HCL 
(pH 6,8), 1% SDS, 5% 2-mercaptoethanol, 5% 
glycerol). Extracts were seperated on a 12% 
SDS-polyacrylamide gel, and transferred to 
a PVDF membrane. NF-YA was visualised 
using specific antibody (C-18, Santa Cruz, 
Heerhugowaard, the Netherlands).
Results
Expression of dominant-negative NF-Y 
inhibits clonogenic growth of BM cells 
A mutant form of NF-YA (YAm29), defective 
in DNA-binding was constructed by Mantovani 
et al.20. YAm29 was shown to have a dominant-
negative effect on transcription regulation by 
wild type NF-Y. To determine the requirement 
of NF-Y in myelopoiesis, we first cloned 
the YAm29 cDNA in the LZRS vector 21;22. 
This vector contains an YAm29-IRES-GFP 
expression cassette, allowing the identification 
of transduced cells. Primary mouse bone 
marrow (BM) cells were transduced with 
YAm29. As a control we transduced cells with 
an empty vector, containing only the GFP 
coding sequence. One day after transduction, 
GFP positive cells were sorted by FACS 
and analysed for YAm29 expression (Figure 
1A). Clear protein expression of YAm29 was 
detected by Western blot analysis in the GFP 
positive fraction, in contrast to GFP negative 
cells or empty vector transduced cells. To 
determine the effect of YAm29 expression on 
colony formation, GFP+ cells were plated in 
methylcellulose and colonies were counted 
after five days. Transduction with YAm29 
resulted in a reduction of granulocytic (CFU-
G) and monocytic (CFU-M) colony formation 
by 70±6 % and 44±19% (n=3) respectively, 
compared to control cells transduced with 
empty vector alone (Figure 1B). In addition 
transduction with YAm29 resulted in a 
reduction of the size of both colony types 
(not shown). The data suggest that NF-Y 
is required for the proliferation of myeloid 
progenitor cells. 
Figure 1. YAm29 inhibits clonogenic growth of 
mouse BM cells. (A) BM cells were transduced 
with empty vector (control) or YAm29 retrovirus, 
sorted for GFP expression and cell lysates were 
resolved on SDS-PAGE and stained using NF-YA 
specific antibody. After sorting there was clear 
expression of YAm29 in GFP positive cells. (B) 
BM cells were transduced with empty or YAm29 
virus and GFP positive cells were plated in 
methylcellulose. 5 days later CFU-G and CFU-M 
colonies were counted. The amount of colonies 
is shown after transduction with YAm29 as a 
percentage relative to the amount of colonies after 
transduction with empty vector.
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Figure 2. YAm29 inhibits proliferation of MAC-
1 negative cells. (A) BM cells were transduced 
with control or YAm29 retrovirus (t= -1) and GFP 
positive cells were grown in liquid medium. Cells 
were counted on a flow cytometer by adding a 
constant amount of beads to each sample (B) 
transduced cells were incubated with MAC-1 
antibody to discriminate between immature 
and mature myeloid cells. Shown are the FACS 
dot plots, forward scatter (FS) against MAC-1 
expression, from day 1 to day 8. The X-mean is the 
mean intensity of the MAC-1 expression (C) The 
expansion of MAC-1 negative cells was calculated 
by multiplying the percentage of MAC-1 negative 
cells, from figure B, with the total amount of cells, 
from figure A.
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Expression of dominant-negative NF-Y 
inhibits the expansion of myeloid progenitor 
cells in vitro
To quantify the inhibitory effect of YAm29 on 
proliferation, FACS-sorted cells were grown 
in liquid culture. The empty vector transduced 
population expanded faster than the YAm29 
transduced population, resulting in a three-fold 
difference on day 6 (Figure 2A). To investigate 
the effect of YAm29 on mature and immature 
cells, the differentiation marker MAC-1 
was used. MAC-1 is expressed on maturing 
myeloid cells, beyond the colony-forming unit 
(CFU) stage 23;24. The percentage of MAC-1 
positive cells increased more rapidly within 
the YAm29 transduced population than in the 
control population. After 8 days, all YAm29 
transduced cells were MAC-1 positive (Figure 
2B), while in the control population around 
17% of the cells were still MAC-1 negative. 
This suggested that the immature cells in the 
control population still proliferated and in the 
YAm29 transduced population proliferation 
was inhibited. The expansion of the MAC-
1 negative cell fraction was calculated by 
multiplying the total amount of cells with the 
percentage of MAC-1 negative cells. This 
revealed that proliferation of the YAm29 
transduced population was completely 
impaired, whereas the MAC-1 negative 
population in the empty vector transduced 
cells still expanded (Figure 2C). The intensity 
of the MAC-1 marker, determined by taken the 
X-mean (Figure 2B), which correlates with the 
maturation stage of the cells, increased at an 
almost comparable pace for both populations. 
This suggested that YAm29 expression did not 
severely affect differentiation. 
To investigate whether the loss of expansion in 
YAm29 transduced BM cells was accompanied 
by increased apoptosis we stained the BM cells 
with annexin V. Within the MAC-1 negative 
population, 9-10% annexin V positive cells 
were found the first 2 days after transduction 
of the empty vector. 23-25% of annexin V 
positive cells were found the first 2 days after 
transduction with YAm29 (Figure 3). This 
higher percentage of annexin V positivity was 
not found in the YAm29 transduced, MAC-1 
positive population. These data suggested that 
loss of NF-Y function resulted in increased 
apoptosis, specifically in myeloid progenitor 
cells.
Expression of dominant negative NF-Y 
inhibits expansion of progenitor cells in 
vivo
Expression of YAm29 resulted in increased 
apoptosis and loss of proliferation of myeloid 
progenitor cells in vitro. To investigate the 
requirement for NF-Y in vivo, we transplanted 
mice with YAm29 expressing BM cells using 
a competitive BM transplantation assay. 
Irradiated CD45.1/CD45.2 heterozygotic mice 
were transplanted with YAm29 transduced 
CD45.1 BM cells and empty vector transduced 
CD45.2 BM cells in a 50/50 ratio, allowing the 
discriminations between YAm29 transduced, 
empty vector transduced and recipient cells. 
Analysis of the mice on day 12 showed a 
predominance of the cells transduced with 
empty vector versus YAm29 transduced cells 
(respectively ±5% compared to ±28% in blood, 
Figure 4A). Both the CD45.1 and the CD45.2 
Figure 3. YAm29 increases apoptosis in MAC-1 
negative cell fraction. BM cells were transduced 
with control or YAm29 retrovirus (t= -1) and GFP 
positive cells were grown in liquid medium. Cells 
were double stained with MAC-1 antibody and 
annexin V and analysed by FACS to assess the 
percentage of apoptotic cells.
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Figure 4. YAm29 inhibits the expansion of BM 
cells in a competitive transplantation assay. (A) 
CD45.2+ BM cells were transduced with YAm29 
retrovirus. CD45.1+ BM cells were transduced 
with control retrovirus. GFP positive cells were 
transplanted, in 50/50 ratio, into irradiated 
(CD45.1+ +CD45.2+) recipients (n=3). Blood, 
spleen, bone marrow and thymus were isolated 
at day 12 and CD45.1+ and CD45.2+ and CD45.1+ 
+CD45.2+ leukocytes were counted. Shown are the 
FACS plots of 2 transplanted mice. (B) Leukocytes 
were stained with the indicated antibodies and 
analysed by FACS. Given are the mean values 
of three mice (C) Both CD45.2+ BM cells and 
CD45.1+ BM cells were transduced with control 
retrovirus. GFP positive cells were transplanted, 
in 50/50 ratio, into irradiated recipients (CD45.1+ 
+CD45.2+). Blood, spleen, bone marrow and 
thymus were isolated at day 12 and CD45.1+ and 
CD45.2+ and CD45.1+ +CD45.2+ leukocytes were 
analyzed by flow cytometry.
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expressing leukocytes at day 12 were mainly 
of the myeloid lineage (±90% MAC-1 positive 
cells, figure 4B). As a control we transplanted 
mice with empty vector CD45.1 BM cells and 
empty vector transduced CD45.2 BM cells in 
a 50/50 ratio. This resulted in equal growth 
of both the CD45.1 and the CD45.2 BM cells 
(Figure 4C). Together these data indicate that 
suppression of NF-Y reduced the proliferation 
of myeloid progenitors.
Discussion
Several hematopoietic genes are a target of 
the transcription factor NF-Y, suggesting a 
role for NF-Y in hematopoiesis. Because NF-
YA -/- mice are embryonic lethal 16, the use 
of a dominant negative form of NF-Y offers 
an elegant way to study the requirement for 
NF-Y in hematopoiesis. We transduced mouse 
BM cells with a dominant-negative form of 
NF-YA. YAm29 has been shown to prevent 
the formation of a functional NF-Y complex 
20. Blocking the function of NF-Y in BM cells, 
in vitro, resulted in a significant reduction of 
granulocytic (CFU-G) and monocytic (CFU-
M) colony formation in size and number. 
To explain this loss of clonogenic potential, 
transduced BM cells were analysed in a liquid 
assay. BM cells transduced with YAm29 
were still able to become MAC-1 positive, 
suggesting maturation was not severely 
affected. However, YAm29 transduction 
completely inhibited the expansion of the 
immature, MAC-1 negative population. This 
suggests that YAm29 inhibits expansion of 
the myeloid progenitor cells, explaining the 
overall decrease in myeloid cells in the liquid 
and colony assays upon YAm29 expression 
and indicating that functional NF-Y is needed 
for expansion of the myeloid progenitor 
cells. Using a competitive transplantation 
assay we studied the requirement for NF-Y 
for proliferation of BM cells in vivo. In these 
experiments, YAm29 also had a negative 
effect on the expansion of progenitor cells 
in comparison to empty vector transduced 
cells. 
Although NF-Y regulates the expression of 
several genes involved in progression through 
the cell cycle and YAm29 expression blocks 
expansion of the MAC-1 negative cells, there 
is still an overall increase in the number 
of BM cells after transduction of YAm29. 
This indicates that YAm29 expression does 
not block cell cycle progression in all cells. 
Possibly the effect of YAm29 expression 
depends on the inhibitions of the expression 
of genes that are involved in maintaining a 
progenitor cell phenotype. One target gene 
of NF-Y is HOXB4. Expression of HOXB4 
is found in immature hematopoietic cells 
and overexpression of HOXB4 results in 
amplified competitive repopulating ability 
in cotransplantation models in mice 25 and in 
extensive expansion of human hematopoietic 
stem cells ex vivo 6. NF-Y is an essential 
factor for induction of HOXB4 expression in 
hematopoietic cells 26. HOXB4 may be one of 
the targets of which the expression is disturbed 
in BM cells transduced with YAm29, leading 
to loss of expansion of the progenitor cells.
Apoptosis was specifically induced upon 
expression of YAm29 in the immature, 
MAC-1 negative, BM cells. This phenotype 
is consistent with the NF-YA conditional 
knock out studies done in primary MEF cells 
16. MEF cells that are devoid of functional 
NF-Y are blocked in their proliferation and 
undergo apoptosis. 
NF-Y is a complex of three proteins. 
Overexpression of only the NF-YA subunit 
promotes the expansion of hematopoietic 
stem cells 17. Here we show that inhibiting 
the function of the trimeric NF-Y complex, 
with a dominant negative protein, reduces the 
expansion of progenitor BM cells. Together, 
these data suggest that the increased expansion 
of immature BM cells upon overexpression of 
only the NF-YA subunit is through increased 
activity of the trimeric NF-Y complex. 
Therefore, the size of the pool of immature 
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hematopoietic cells may be regulated through 
(de-)activating NF-Y. 
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Isolation of FRET-positive cells
 using single 408 nm laser flow cytometry
Background: Flow cytometry may be used to isolate large amounts of living, fluorescently 
labelled cells. Certain fluorescent labels, like ECFP and EYFP, allow the assessment of 
direct protein-protein interaction, in situ, by FRET. However, current flow cytometric 
methods either require elaborate technical adaptations or, using a single laser protocol, 
are hampered by background signal. We optimized a single 408 nm laser protocol to 
detect FRET between ECFP/EYFP-tagged proteins.
Methods: Cell lines, stably expressing ECFP, EYFP, ECFP and EYFP or an EYFP-ECFP 
fusion protein, were used to design the settings for the flow cytometer to detect FRET-
positive cells using a single 408 nm laser. Using these settings, interactions between the 
subunits of the transcription factor NF-Y were studied. 
Results: Flow cytometric analysis of the cells expressing an EYFP-ECFP fusion protein, 
yielded a discrete FRET-positive population. Using the same settings, in cells expressing 
NF-YB-CFP and NF-YC-YFP fusion proteins, FRET could also be detected. These cells 
were sorted and FRET was confirmed by confocal microscopy. 
Conclusion: FRET positive cells, expressing ECFP- and EYFP-tagged proteins, can be 
detected using single 408 nm laser excitation, with low background signal. This allows 
high-throughput analysis and isolation of viable FRET positive and negative cells for 
subsequent biological experiments. 
Introduction
Fluorescence Resonance Energy Transfer 
(FRET) occurs when one fluorochrome (the 
donor) excites another fluorochrome (the 
acceptor) through direct resonance energy 
transfer. Upon excitation, the donor transfers 
its energy to the acceptor and the acceptor 
emits photons at its own characteristic 
wavelength. This phenomenon may occur 
when the emission spectrum of the donor 
significantly overlaps with the excitation 
spectrum of the acceptor. FRET is dependent 
on the physical distance between the two 
fluorochromes. Each donor/acceptor couple 
has a characteristic distance for which the 
FRET efficiency is 50%, meaning that 50% 
of the excited fluorochromes transfer their 
energy by FRET. This distance is usually 
between 30 and 60å, which is roughly the size 
of a protein. The FRET efficiency will usually 
be less than 1%, and therefore undetectable, 
if the distance between donor and acceptor is 
more than 100å (1-6).
In most biological assays FRET is measured 
using fluorescence microscopy (7,8). However, 
flow cytometry may offer some advantages. 
Using flow cytometry, large amounts of living 
cells can be studied in seconds. Additionally, 
cells of interest may be sorted for further 
biological studies. The determination of 
FRET with flow cytometry has been used 
to measure the interaction of cell surfaces 
molecules (9). In these experiments different 
antibodies, one coupled to a donor and one 
to a acceptor fluorescent dye, were used. 
Development of variants of the Green 
Fluorescent Protein (GFP) has made it 
possible to study intracellular proteins as well. 
A FRET couple that may be used in biological 
assays consists of the GFP variants, Enhanced 
Cyan Fluorescent Protein (ECFP; as the 
donor) and Enhanced Yellow Fluorescent 
Protein (EYFP; as the acceptor) (1,3). These 
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proteins can be cloned as fusion partner to 
any protein of interest. Because 50% FRET 
efficiency for ECFP/EYFP occurs at 50 å (4), 
the fusion partners must be in close proximity 
to each other for this to happen. Therefore, 
FRET, using ECFP/EYFP, indicates that two 
proteins directly interact. These measurements 
can be done in living cells with proteins at 
their appropriate localization.
Flow cytometry has been used to study FRET 
between EYFP and ECFP (10-12). In the first 
two studies, the flow cytometer was equipped 
with two lasers and a set up using a time delay 
module and interlaser compensation to detect 
FRET. This allows, for each individual cell, 
the measurement of the amount of EYFP and 
ECFP emission due to direct laser excitation, 
but also the amount of EYFP emission due to 
FRET (FRET-EYFP). However, this setup is 
not easily applicable to all flow cytometers. 
The third study used a 458 nm laser to detect 
FRET. However, as the authors indicate, 
the drawback of this set up is that at this 
wavelength both EYFP and ECFP are excited. 
Fluctuations in EYFP expression will easily 
interfere with FRET detection in this protocol. 
When FRET efficiencies are low, most signal 
with 458 nm excitation will be from direct 
laser excitation of EYFP and not from FRET. 
Theoretically, a laser of approximately 400 
nm would be preferable, as at this wavelength 
ECFP will preferentially be excited. We 
equipped a flow cytometer with a 408 nm 
laser and designed and tested a single laser 
flow cytometer protocol.
Materials and Methods
DNA vectors
pECFP-C1 and pEYFP-C1 were from 
Clontech (Palo Alto, CA, USA). NF-YA, -B 
and -C were cloned from pSG5 vectors (a 
kind gift of Dr. R. Mantovani, University of 
Milan, Italy) into pEYFP-C1 and pECFP-C1. 
The pSG5-NF-YA,  pSG5-NF-YB and pSG5-
NF-YC vectors were used as template in PCR 
reactions using forward primers containing 
a BglII restriction site and reverse primers 
containing an EcoR1 site for directional 
cloning in the pEYFP/ECFP-C1 vectors.
ECFP-EYFP fusion construct
The EYFP-ECFP fusion construct was a 
kind gift of Dr. F.J. van Kuppeveld (UMC, 
Nijmegen) (13). The fusion protein separates 
EYFP from ECFP with a 35 amino acid 
linker. FRET efficiency for this construct has 
been determined with fluorescence lifetime 
imaging (FLIM). The fluorescence lifetime 
of a donor molecule (the time the molecule 
spends in the excited state) is reduced by 
FRET. Fluorescence lifetime imaging may be 
used to calculate FRET efficiency (6,14). A 
lifetime of 1.95 ns was described for ECFP in 
the EYFP-ECFP fusion construct, compared 
to a lifetime for free ECFP of 2.5 ns. This 
demonstrated a FRET efficiency of around 
22% for the EYFP-ECFP fusion construct 
(13).
Cell culture and transfection.
Hep3B cells and HEK293 cells were cultured 
in D-MEM medium (Gibco, Gaithersburg, 
MD) supplemented with 10% fetal calf 
serum (Gibco). Transfections were done with 
calcium phosphate precipitates according to 
standard procedures. After 18-24 hours, cells 
were washed and harvested by trypsinization 
(Gibco) and taken up in HBSS (Cambrex, 
Verviers, Belgium). Transfections were done 
in a 1:1 molar ratio. The apparent FRET 
efficiency will be negatively influenced 
when donor molecules are present in higher 
concentrations than the acceptor molecules. 
Therefore, the relative expression of donor and 
acceptor molecules were monitored by flow 
cytometry and spectral imaging. In addition, 
the absolute expression levels were adjusted 
using appropriate concentrations of plasmid 
in order to minimize “false positive FRET” 
signal caused by direct EYFP excitation by 
the 408 nm laser.
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Flow cytometric analysis and sorting
Cells were analysed on a Epics Altra flow 
cytometer (Beckman Coulter, Miami, Florida). 
To asses the amount of EYFP expression, 
EYFP emission was detected at 575 nm after 
excitation with an 488 nm argon laser line. 
To detect FRET, the flow cytometer settings 
were as follows (Fig. 1): Excitation was with 
a diode, Vioflame, laser (408 ± 8 nm, Coherent 
Inc., Santa Clara, CA) running at 25mW. 
Signal below 420 nm was blocked with a 420 
nm long pass filter. ECFP was separated from 
EYFP using a 475 nm dichroic mirror and 
ECFP was detected using a 465±15 nm band 
pass filter. FRET-EYFP was detected using 
a 600 nm dichroic mirror and a 575±15 nm 
band pass filter. Due to spectral overlap, ECFP 
will emit some light in the EYFP detector. 
Electronic compensation was set using cells 
transfected with ECFP only.
Acceptor Photobleaching FRET 
measurements
Acceptor photobleaching FRET microscopy 
was performed on a Zeiss LSM510Meta 
confocal microscope (Carl Zeiss GmbH, 
Jena, Germany) using a Plan-Apochromat 
63x oil immersion objective with a numerical 
aperture (NA) of 1.4. Excitation of ECFP 
was accomplished using the 458 nm Argon 
laser line and ECFP emission was detected 
using a HFT458/514 main dichroic splitter, a 
NFT545 dichroic splitter, acting as short-pass 
filter and a 470-500 nm band pass filter. EYFP 
was excited using the 514 nm Argon line 
and the selective photobleaching of EYFP in 
acceptor photobleaching FRET experiments 
was accomplished by operating this line at 
full power. EYFP emission was detected 
using the same HFT458/514 and NFT545, 
now acting as long-pass filter, and a 535-590 
nm band pass filter. Operating in line-wise 
multitrack mode, the ECFP and EYFP images 
were collected almost simultaneously and 
using this excitation/detection protocol the 
ECFP channel was essentially cross-talk free. 
Apparent energy transfer efficiencies E (6) 
were calculated from 
postROI
D
preROI
D
I
IE
,
,1 -=
.   
   
Here, ID
ROI, pre
 and ID
ROI, post
 refer to the intensity 
of the donor (D; ECFP) in a region of 
interest (ROI) before and after the selective 
photobleaching of the acceptor (EYFP). 
The relative expression of donor and acceptor 
molecules in each cell was determined by 
spectral imaging analysis using the META 
detector (458 nm excitation, HFT458/514 
main dichroic, spectral decomposition and 
Figure 1.  Flow cytometer settings for detecting 
FRET. Cells were excited using a 408 nm laser 
line. All outcoming signal under 420 nm was 
blocked using a 420 nm long pass filter in front of 
detector 1. Using a dichroic mirror, signal between 
420 and 475 nm was directed to detector 2. Here, 
ECFP was detected using a 465±15 band pass filter. 
Using a dichroic mirror, signal between 475 and 
600 nm was directed to detector 3. Here, EYFP was 
detected using a 575±15  nm band pass filter.   
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subsequent detection using the 32 channel 
PMT array detector META). Despite the 1:1 
molar transfection ratio, the spectral ratios 
deviate from 1 because FRET results in a 
lowered ECFP emission and enhanced EYFP 
emission. Typically, spectral ratios EYFP/
ECFP (530/480) were 1.7 +/- 0.2 in the case 
of the ECFP-EYFP fusion protein, and 1.4 
+/- 0.1 for the NF-YB-CFP and NF-YC-YFP 
co-expressing cells.
Results
To design the flow cytometer settings for 
detecting FRET-positive cells, four different 
cell cultures (Hep3B cells) stably expressing 
different EGFP variants were established by 
cell sorting, resulting in polyclonal cultures 
with cells expressing high to very low levels 
of the indicated proteins (Fig. 2). Two cultures 
were made that stably expressed either EYFP 
or ECFP alone. As a negative control for 
FRET, a culture was established expressing 
both EYFP and ECFP independently. As a 
positive control for FRET, a culture expressing 
an EYFP-ECFP fusion protein was made (see 
material and methods). 
Characteristics of the cell cultures were 
determined using fluorescence microscopy. 
No difference was found in localization of 
Figure 2. Detection of ECFP and EYFP 
expression in stably transfected Hep3B cells. 
Cells were transfected with an EYFP-ECFP 
fusion construct (upper panel) or two plasmids, 
one containing ECFP and one containing EYFP 
(lower panel). Cells were cultured and stable 
transfectants were selected by cell sorting. Cells 
were analysed by flow cytometry and fluorescence 
microscopy. Flow cytometric detection of ECFP 
was by excitation with a 408 nm laser line and 
EYFP was detected by excitation with a 488 nm 
laser line. ECFP and EYFP is plotted against 
forward scatter (FS).
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the fluorescent proteins between the cells 
expressing the EYFP-ECFP fusion protein and 
the ECFP and EYFP proteins separately (Fig. 
2). Cells were analysed to check whether EYFP 
and ECFP were expressed at approximately 
equal amounts. Ratios and absolute levels 
were determined by a combination of spectral 
imaging and flow cytometry, as described 
in materials and methods. ECFP and EYFP 
transfected cells showed over 95% co-
expression of both proteins in a comparable 
ratio. Because EYFP and ECFP do not bind to 
each other, this culture was used as a negative 
control for FRET studies.
The FRET efficiency of the cells expressing the 
EYFP-ECFP fusion construct was measured 
using confocal fluorescence microscopy and 
acceptor photobleaching. Because the donor 
molecule transfers part of its energy during 
FRET, it will emit more light in the absence of 
an acceptor molecule. Therefore, FRET can be 
detected by bleaching the acceptor molecule 
and measuring the increase in emission of the 
donor. EYFP was bleached in a selected region 
by operating a 514 nm laser line at full power. 
ECFP emission was measured before and 
after bleaching in the same region and FRET 
efficiency was determined by dividing these 
two values. This yielded a FRET efficiency for 
the EYFP-ECFP transfected cells of 21±5% 
(Fig. 3), which was comparable to the 22% 
efficiency measured by FLIM (see materials 
Figure 3. Detection of FRET by confocal 
microscopy in Hep3B cell expressing an 
EYFP-ECFP fusion construct. (A) Confocal 
microscopy was used to measure the intensity 
of ECFP and EYFP emission in cells expressing 
an EYFP-ECFP fusion construct. EYFP was 
bleached by selective photobleaching with a 514 
nm laser line at full power. The arrow indicates the 
bleached region. The increase in ECFP emission 
after photobleaching was used to determine the 
FRET efficiency (see material and methods). In 
the lower image the ECFP emission intensity after 
bleaching is subtracted from the ECFP emission 
intensity before bleaching to visualise the increase 
in ECFP emission. The mean FRET efficiency 
was determined by bleaching several different 
cells. (B) The mean fluorescence intensity of the 
selected region, ECFP and EYFP, was monitored 
for 2 minutes before bleaching and 2 minutes after 
bleaching. 
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and methods). This indicated that these cells 
were a suitable positive control to design the 
flow cytometer settings to detect FRET.
To preferentially excite ECFP, we added 
a 408 nm laser to our flow cytometer. The 
ECFP expressing cells were used to determine 
the required electronic compensation, 465 
detection out of 575 detection (not shown). 
Subsequently, this protocol was used for all 
acquisitions. Mean ECFP emission levels, and 
therefore expression levels, were comparable 
in the culture expressing ECFP alone or ECFP 
and EYFP separately (Fig. 4, first column). 
The EYFP-ECFP fusion protein expressing 
cells showed a slightly reduced level of ECFP 
emission in comparison to the other ECFP 
expressing cultures, compatible with the 
occurrence of FRET. At 488 nm excitation, 
EYFP emission levels were comparable in 
the cells expressing EYFP alone, EYFP and 
ECFP separately and cells expressing the 
fusion construct (Fig. 4, second column). 
At 408 nm excitation, EYFP emission could 
only be detected in the EYFP-ECFP fusion 
protein expressing cells (Fig. 4, third column), 
indicating FRET.
Next, we investigated whether we could 
detect FRET between two separate proteins 
that are known to interact. The transcription 
factor NF-Y consists of three subunits NF-
YA, -B and -C. NF-Y is, as a complex, able 
to bind to CCAAT-boxes in the DNA and to 
the basal transcription machinery through 
binding of TBP (15,16). In this way NF-Y 
regulates the expression of many cell cycle 
related genes (17). NF-YA and NF-YB were 
fused to ECFP and all three subunits were 
fused to EYFP. 
Different combinations of these constructs 
were transiently transfected and monitored 
for the presence of FRET using the same 
settings as described above. EYFP emission 
Figure 4. Detection of FRET 
by flow cytometry in Hep3B 
cell expressing an EYFP-
ECFP fusion construct. Four 
cell lines were used to design 
the flow cytometry settings to 
detect FRET; cells expressing 
only ECFP (row 1), only 
EYFP (row 2), both ECFP and 
EYFP separately (row 3), the 
EYFP-ECFP fusion construct 
(row 4). EYFP emission was 
measured using the 488 nm 
excitation and plotted against 
forward scatter (second 
column). In the same cells 
FRET was measured using the 
408 nm laser (column one and 
three). In column three ECFP 
emission is plotted against 
FRET-EYFP emission.
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was detected by excitation with the 408 nm 
laser in cells transiently transfected with 
NF-YB-ECFP and NF-YC-EYFP (Fig. 5A). 
This indicated that co-expression of NF-YB-
ECFP and NF-YC-EYFP resulted in FRET. 
Excitation with the 408 nm laser did not 
result in EYFP emission in cells expressing 
NF-YA-ECFP and either NF-YB-EYFP or 
NF-YC-EYFP. Possibly, within the NF-Y 
complex, the ECFP-tag on NF-YA is too far 
apart from the EYFP-tag on NF-YB and NF-
YC for FRET to occur. 
The cell cultures described above, all expressed 
the EYFP proteins at comparable levels of 
between 1 to 30 times over background. 
We investigated whether FRET could still 
be detected in cells expressing extremely 
high levels of EYFP. Cells were transfected 
with NF-YB-CFP and/or NF-YC-YFP, with 
high efficiency and harvested after a two-
day incubation. These cells showed high 
EYFP emission upon excitation with the 
488 nm laser. (Fig. 5B, first row). Although 
FRET was detected  in cells expressing 
NF-YB-CFP and NF-YC-YFP, some cells 
expressing only NF-YC-YFP were excited 
Figure 5. Detection and sorting of transiently 
co-transfected, FRET positive cells by flow 
cytometry. Cells were measured by flow 
cytometry using 488 nm excitation to detect 
EYFP. Using 408 nm excitation ECFP and 
FRET was detected. (A) Cells were transiently 
transfected with NF-YA-ECFP and NF-YB-
EYFP or NF-YC-YFP or NF-YB-ECFP 
and NF-YC-YFP. (B) Cells were transiently 
transfected with NF-YB-CFP and/or NF-YC-
YFP and untagged NF-YA (first two columns) 
or the same vectors were diluted 8 times with 
an empty vector (last two columns). EYFP 
was measured by excitation with the 488nm 
laser (column 1 and 3). ECFP and EYFP were 
measured by excitation with the 408nm laser 
(column 2 and 4). 
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with the 408 nm laser (Fig. 5B, second row). 
This indicated that high EYFP expression 
interfered with FRET detection. Diluting 
the transfection mixture with empty vector 
resulted in decreased expression levels 
of EYFP/ECFP-tagged proteins. In these 
cells a FRET signal was found only in cells 
expressing both NF-YB-CFP and NF-YC-
YFP (Fig. 5B, compare column 1 and 2 with 
3 and 4). This indicated that expression levels 
need to be under a threshold to get a pure 
FRET-positive population. This threshold 
was determined by making a dilution series 
of cells expressing high, to very low amounts 
of only EYFP (not shown). Analysis revealed 
that cells expressing less than 30 times over 
background, as measured with 488 nm 
excitation, were not detected in the EYFP/
FRET channel upon 408 nm excitation. Taken 
into account this treshold, EYFP emission 
after dilution (figure 5B, last column) could 
only be explained by FRET.
To confirm that the cells transfected with 
NF-YB-CFP and NF-YC-YFP were FRET-
positive, cells were sorted and cytospins 
were analysed by confocal fluorescence 
microscopy. Both cells expressing high levels 
of NF-YB-ECFP and NF-YC-EYFP and cells 
expressing low levels were sorted. FRET 
efficiency was 9 ± 1% in all cells, indicating 
that in all sorted cells, NF-YB and NF-YC 
interacted.
Discussion
The study of protein-protein interactions has 
been greatly improved by FRET microscopy, 
making it possible to study interactions in situ, 
within the living cell. Detecting FRET-positive 
cells by flow cytometry adds the possibility to 
analyse protein-protein interactions in living, 
non-homogenous cell cultures and allows the 
isolation of FRET positive and negative cells. 
Here, we describe a method to detect FRET-
positive cells using single 408 nm laser flow 
cytometry. The protocol may be used to detect 
FRET in cells transfected with two plasmids 
encoding tagged-proteins of interest.
At 408 nm excitation, ECFP is near its 
absorbtion maximum, whereas EYFP is 
excited at a minimal level. Therefore, at this 
wavelength, EYFP excitation will interfere 
minimally with the detection of FRET. 
Using this protocol, FRET could be detected 
by monitoring the emission of EYFP. The 
flow cytometer settings were determined by 
making use of a construct in which EYFP is 
fused to ECFP. By two different methods the 
characteristics of this construct have been 
determined. FLIM demonstrated a FRET 
efficiency of around 22% for this construct 
(13). Photobleaching studies by confocal 
microscopy of cells, stably transfected with 
the ECFFP-EYFP fusion construct also 
confirmed that these cells were FRET positive, 
indicating that these cells were suitable to 
design the settings for a flow cytometry 
protocol. 
Upon excitation with the 408 nm laser line 
a clear FRET-positive population could be 
detected in cells expressing a EYFP-ECFP 
fusion protein. Cells expressing only EYFP 
were not excited with the 408 nm laser line. 
This indicated that at the EYFP expression 
levels in these cells, direct excitation of EYFP 
with the 408 nm laser line did not interfere 
with FRET detection. Only cells expressing 
high amounts of EYFP gave some signal in 
the in the 575 nm detector (Fig. 5B). This 
indicated that with the 408 nm laser line EYFP 
was still somewhat excitated. Therefore, in 
FRET studies, using single 408 nm excitation 
it is necessary to use a control population of 
cells, expressing only the EYFP construct, 
that expresses equal amounts of EYFP as 
the FRET-positive cells. To accomplish this, 
transfection efficiency can, amongst others be 
controlled by diluting the transfection mixture 
with empty vector DNA. 
The three subunits of  NF-Y are able to form 
one complex. We were able to detect FRET 
between subunits NF-YB and NF-YC but not 
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between NF-YA and either NF-YB or NF-YC. 
This suggested that either tagged NF-YA was 
no longer able to form a complex with NF-
YB and C, or that the orientation and distance 
between the tag on NF-YA and NF-YB or 
NF-YC were not optimal for FRET to occur. 
The detection of FRET with fluorescence 
microscopy in sorted cells expressing NF-
YB-ECFP and NF-YC-EYFP confirmed that 
the 408 nm single laser can be used to detect 
FRET in cells expressing ECFP- and EYFP-
tagged proteins from transiently transfected 
cDNAs.
In summary, we show that a 408 nm single 
laser is a ready-to-use tool to detect FRET, 
making it possible to isolate living FRET-
positive and negative cells, expressing 
ECFP/EYFP-tagged proteins, for subsequent 
biological experiments.
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Summary and perspectives
Treatment of acute promyelocytic leukemia 
(APL) with high dose retinoic acid (ATRA) 
forces terminal differentiation of the leukemic 
blasts towards mature granulocytes with 
a normal, limited lifespan. This treatment 
constitutes one of the first clinically relevant 
differentiation-induction therapies in cancer. 
In this thesis we show that the PML-RARα 
fusion protein not only interferes with the 
transcription of regular retinoic acid receptor 
target genes, but may also interfere with the 
expression of Sp1-NF-Y regulated genes, 
defining a novel class of target genes and a 
gain-of-function for the oncoprotein.
PML-RARα is the causative oncogene in 5-
10% of the cases of acute myeloid leukemia. 
The fusion protein interferes with the function 
of both non-rearranged PML and retinoic 
acid receptor-α counterparts. PML-RARα 
silences normal retinoic acid receptor target 
genes, but in response to high dose retinoic 
acid, it (re)activates the transcription of genes, 
forcing the cells into differentiation. We show 
that ID1 and ID2 are direct retinoic acid 
target genes in APL cells. The ID1 and ID2 
promoters are activated by PML-RARα but, 
unexpectedly, not by wild type RARα/RXR. 
Our data support a model in which the PML-
RARα fusion protein regulates a novel class of 
target genes by the interaction with Sp1-NF-Y 
transcription factors, without directly binding 
to the DNA. 
We set out to identify genes that are responsive 
to ATRA and we investigated the role of 
these genes in ATRA-induced differentiation. 
In APL cells ID1 and ID2 are rapidly 
upregulated in response to ATRA, both at 
the mRNA and protein level. Treating cells 
with cycloheximide, an inhibitor of protein 
synthesis, did not inhibit induction of these 
genes, suggesting that PML-RARα directly 
regulated these genes. ID proteins are general 
inhibitors of basic Helix-Loop-Helix (bHLH) 
transcription factors. BHLH transcription 
factors are involved in the specification 
of the mesoderm during embryogenesis 
and are involved in the differentiation of 
mesodermal tissues like muscle, bone and 
blood (Nederbragt et al., 2002). The rapid 
upregulation of ID1 and ID2 in APL cells 
suggested a role for these proteins in APL cell 
differentiation. Therefore, we overexpressed 
ID1 and ID2 in the APL cell line NB4. 
Overexpression inhibited proliferation and 
induced a G0/G1 accumulation, indicating 
a role for ID1 and ID2 in ATRA-induced 
differentiation in APL.
Chapter 2. To investigate the mechanism 
by which PML-RARα  regulates the 
transcriptional activation of ID1 in response 
to ATRA, we cloned the ID1 promoter in a 
luciferase reporter construct. Surprisingly, we 
found that the promoter was transactivated 
by PML-RARα in a retinoic acid dependent 
manner, but not by unrearranged RARα/RXR. 
To identify the regulatory DNA sequences 
through which the induction by PML-RARα 
was mediated, several deletion mutants were 
constructed. Deletion mutants that lacked 
all (even remotely) consensus retinoic acid 
response elements were still transactivated 
by PML-RARα. To test whether PML-RARα 
might transactivate the ID1 promoter without 
directly binding to the DNA, we used a PML-
RARα construct in which the DNA binding 
domain was deleted (PML-RAR/∆R). While 
we confirmed that PML-RAR/∆R was unable 
to transactivate a promoter containing a 
well-defined retinoic acid response element 
from the RARβ promoter, it could still 
transactivate the ID1 promoter. This indicated 
that transactivation of ID1 by PML-RARα 
occurred without direct binding of PML-
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RARα to the DNA. When the coiled-coil 
domain of PML-RARα was deleted (PML-
RAR/∆CC) transactivation was abolished. 
As the coiled-coil domain is involved in 
protein-protein interactions, this suggested 
that the transactivation of ID1 is dependent 
on homodimerisation and/or interaction with 
other protein(s) mediated through the PML-
part of the chimera. Further deletion and point 
mutants identified the site in the ID1 promoter 
that was necessary for PML-RARα mediated 
transactivation, showing that a CCAAT box 
(binding site for the transcription factor NF-Y) 
and adjacent GC box (binding sites for Sp1) 
were essential for transactivation. 
NF-Y is a trimeric protein complex consisting 
of the subunits NF-YA, NF-YB and NF-YC. 
All three subunits are needed for the complex 
to bind to the DNA. When a dominant-
negative form of NF-YA (YAm29) was 
used, transactivation of the ID1 promoter by 
PML-RARα was abolished. To test whether 
PML-RARα could be recruited to the DNA 
through binding to either Sp1 or one of the 
NF-Y subunits, we performed GST-pull 
down experiments. These showed that PML-
RARα may bind to Sp1, whereas no direct 
interaction with any of the NFY subunits 
was observed. Additionally, in chromatin 
immunoprecipitation assays, using anti-PML 
antibodies, we were able to precipitate the 
ID1 promoter, both in U937 cells expressing 
PML-RARα and U937 cells not expressing 
PML-RARα, suggesting that both PML-
RARα, and also the normal PML protein is 
present on the ID1 promoter. From HEK293 
cells, ectopically expressing FLAG-tagged 
PML-RARα, we were able to ChIP the ID1 
promoter, using anti-FLAG antibody. The 
data suggest a model in which PML-RARα 
binds to a DNA-bound SP1-NF-Y complex, 
rendering the expression of ID1 sensitive 
to ATRA. The effect of PML-RARα on the 
endogenous ID1 gene was tested using a U937 
cell line that is stably transfected with a Zn2+-
inducible PML-RARα expression cassette. In 
PML-RARα expressing U937 cells, ATRA 
strongly induced ID1 mRNA and protein 
expression, contrary to U937 cells lacking 
PML-RARα. Additionally, we found that the 
ID2 gene, in response to ATRA, is regulated 
by the same mechanism as the ID1 gene.
Together, this implicates that apart from 
deregulating RARα target genes, PML-RARα 
deregulates an additional class of genes. We 
show that the HES1 gene is regulated in a 
comparable manner to ID1 and ID2, suggesting 
indeed that the mechanism described is more 
general. The gain-of-function for PML-RARα 
may contribute to the successful treatment of 
acute promyelocytic leukemia. 
Chapter 3. P53 has been implicated in the 
induction of apoptosis in genetically damaged 
cells, and p53-mediated eradication of cells 
is one of the major mechanisms protecting 
us against tumorigenesis. Disruption of p53 
function is a common characteristic of cancer 
cells, and TP53 is considered to be the most 
frequently mutated oncogene in human cancer. 
One of the most important negative regulators 
of p53 is the MDM2 protein. MDM2 binds 
p53, blocks p53-mediated transactivation 
and targets p53 for proteasomal degradation. 
In leukemia, p53 is rarely mutated, but 
its function may be deregulated by other 
mechanisms, for instance by overexpression 
of MDM2.
We tested whether PML-RARα expression 
would influence MDM2 expression. Induction 
of PML-RARα in U937 cells did not change 
MDM2 mRNA expression levels, but at the 
protein level, MDM2 was highly upregulated. 
Therefore, p53 may be deregulated in APL 
cells by increased levels of MDM2 protein. 
This mechanism may contribute to the 
transformation in APL.
A novel class of small molecules, Nutlins, 
was developed recently (Vassilev et al., 2004). 
Nutlins disrupt the binding of MDM2 to 
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p53, thereby inhibiting p53 degradation and 
activating p53-dependent apoptotic pathways. 
We analyzed the effect of Nutlins on primary 
APL patient samples. Cells from all APL 
patients showed, in variable degree, a dose- 
and time-dependent increase in apoptosis. 
We conclude that PML-RARα expression 
enhances MDM2 protein levels, and that APL 
cells are sensitive to MDM2 antagonists. 
Chapter 4. As shown in chapter 2, PML-
RARα may regulate gene transcription 
through binding of a Sp1-NF-Y DNA-bound 
complex. To determine the biological role 
of NF-Y in hematopoiesis we expressed a 
dominant negative form of NF-Y in murine 
bone marrow cells by retroviral transduction. 
Inhibition of NF-Y function resulted in a 
significant reduction of granulocytic (CFU-G) 
and monocytic (CFU-M) colony formation 
by 70% and 44 %, respectively. To study 
this reduction in more detail, we analysed 
the effect of dominant negative NF-Y on 
proliferation, differentiation and apoptosis. 
In more mature, MAC-1 positive cells, no 
differences in proliferation, differentiation and 
apoptosis were observed between dominant 
negative NF-Y- and vector- transduced 
cells. In contrast, the expansion of MAC-1 
negative cells was completely abrogated by 
the expression of dominant negative NF-Y. 
Moreover, the inhibition of NF-Y function 
resulted in a significant increase in apoptosis 
in MAC-1 negative cells. Competitive 
transplantation of BM cells to irradiated mice, 
showed a repopulation advantage of vector-
transduced cells versus dominant negative 
NF-Y transduced cells. This indicates that 
NF-Y regulates the expansion of the myeloid 
progenitor cells.
Chapter 5. To study the interaction of the 
different NF-Y subunits in living cells, we 
developed a flow cytometric protocol, to 
detect fluorescence resonance energy transfer 
(FRET). FRET occurs when one fluorochrome 
(the donor) excites another fluorochrome 
(the acceptor) through direct resonance 
energy transfer. FRET only occurs when 
molecules are close together and may be used 
to investigate whether proteins interact. We 
developed a flow cytometric protocol to detect 
FRET between ECFP/EYFP-tagged proteins. 
With this protocol we were able to detect 
FRET between NF-YB-CFP and NF-YC-YFP 
and we were able to sort the FRET-positive 
and FRET-negative cells. This protocol allows 
high-throughput analysis and isolation of 
viable FRET positive and negative cells for 
subsequent biological experiments. 
PML-RARα in transformation. The 
transforming effect of PML-RARα may be 
explained by 4 mechanisms.
1) PML-RARα has a dominant negative 
effect on RARα. PML-RARα binds to RARα 
binding elements, resulting in silencing of 
RARα target genes. Wild-type RARα has a 
ligand-dependent and a ligand–independent 
activation domain. PML-RARα is able to 
repress the transcription of RARα target 
genes.
2) PML-RARα has a dominant effect on PML. 
PML-RARα binds and translocates the PML 
protein to an aberrant nuclear localization, 
antagonizing the role of PML in growth 
suppression and apoptosis. Additionally, 
PML-RARα may sequester PML binding 
partners and inhibit their function.
3) PML-RARα sequesters RXR. Apart from 
being a heterodimerization partner for RARα, 
RXR is a heterodimerisation partner for many 
nuclear hormone receptors. PML-RARα may 
block the function of these other nuclear 
hormone receptors by sequestering RXR. 
4) The PML-RARα fusion protein regulates 
other genes besides RARα targets. PML-
RARα homodimers bind to a larger variety of 
direct repeats than RARα/RXR. Additionally, 
PML-RARα binds to the DNA via a Sp1-NF-
Y complex. PML-RARα may repress the 
transcription of these genes.
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PML-RARα, its role in the ATRA-response.
PML-RARα positive APL cells are sensitive 
to ATRA. In response to ATRA the APL cells 
differentiate into mature granulocytes and 
finally go into apoptosis. Recent studies show 
that APL cells are also sensitive to arsenic 
trioxide (ATO) (Douer and Tallman, 2005). 
ATO induces partial differentiation and, at 
higher dose, apoptosis of APL cells (Miller, 
Jr. et al., 2002). Common to both treatments is 
the induction of degradation of PML-RARα, 
suggesting that degradation of the oncoprotein 
is important for the response of the APL 
cells. In chapter 3 we show that APL cells are 
sensitive to Nutlins. We found that Nutlins 
induce a relative decrease in numbers of 
microspeckled cells and increase in numbers 
of cells with normal PML-nuclear bodies. 
FISH showed no relative decrease in numbers 
of cells with a t(15;17) translocation (data not 
shown). This suggests that also Nutlins induce 
degradation of the PML-RARα protein. 
It is tempting to speculate that the APL 
cells differentiate and become apoptotic 
as a result of targeted degradation of the 
oncoprotein. However, several arguments 
indicate that PML-RARα is an active inducer 
of differentiation upon treatment with ATRA 
as well.
PLZF-RARα positive APL cells are, in 
contrast to PML-RARα positive APL cells, 
less sensitive to ATRA and only differentiate 
in the presence of other costimuli (Jansen et 
al., 1999). Still PLZF-RARα is, like PML-
RARα, degraded in response to ATRA (Koken 
et al., 1999), suggesting that degradation of 
the oncoprotein is not sufficient for terminal 
differentiation in response to ATRA. 
ATRA is a ligand for RARα. ATRA serves 
also as a ligand for PML-RARα and PLZF-
RARα. However. PML-RARα only activates 
transcription in the presence of high-dose 
ATRA and PLZF-RARα does not activate 
transcription in response to ATRA because of 
an ATRA-independent co-repressor complex 
bound to the PLZF part of the fusion protein. 
This suggests that ATRA may activate genes 
in PML-RARα positive APL cells that are 
not activated in PLZF-RARα positive APL 
cells. These genes may be responsible for the 
induction of differentiation.
APL is the only type of AML sensitive to 
ATRA, suggesting an active role for PML-
RARα in the ATRA response. An active role 
for PML-RARα in induction of differentiation 
in APL cells also follows from experiments 
showing that PML-RARα increases the 
sensitivity to ATRA when expressed in 
certain non-APL cells and restores ATRA-
sensitivity in cell lines carrying mutations 
in RARα (Grignani et al., 1993; Grignani et 
al., 1996; Ruthardt et al., 1997). PML-RARα 
re-expression restores ATRA-sensitivity 
in APL cells with constitutive degradation 
of the fusion protein (Fanelli et al., 1999). 
Additionally, point mutations have been 
identified in the ATRA-binding domain 
of PML-RARα in ATRA-resistant APL 
patients. 
Together these data suggest that activation of 
genes, in response to ATRA, by PML-RAR, 
results in the induction of differentiation 
in APL. The results from chapter 3 
show that degradation of PML-RARα 
results in downregulation of MDM2 and 
subsequent apoptosis. Therefore, the terminal 
differentiation in response to ATRA is 
explained by the combination of sequential 
effects. First, activation of PML-RARα target 
genes results in differentiation of the cells 
and later, degradation of PML-RARα cancels 
the repressive effect on signalling pathways, 
resulting in apoptosis.
PML-RARα is able to target the same genes 
as normal RARα. The p21(waf1/cip1) promoter 
contains a retinoic acid response element, 
1200 bp upstream of its transcription start 
site, and is a target of RARα/RXR (Liu et 
al., 1996). P21 is a cyclin-dependent kinase 
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inhibitor and uprgegulation of p21 causes cells 
to arrest in G1 and withdraw from the cell 
cycle, suggesting that p21 is directly involved 
in ATRA-dependent differentiation. The 
RARβ has also been identified as target gene 
for RARα/RXR (de et al., 1990). However, no 
role for RARβ in APL differentiation has been 
described. Both genes are also transactivated, 
in response to ATRA, by PML-RARα.
In this thesis, we present a model showing a 
gain-of-function for the PML-RARα fusion 
protein. In response to ATRA, PML-RARα 
activates a class of genes that is not activated 
by normal RARα. This activation is dependent 
on binding of PML-RARα to the transcription 
factor Sp1. PLZF-RARα was, like RARα, 
unable to activate transcription of these 
genes, which underlines the importance of the 
PML-part of PML-RARα in the activation of 
transcription, and possibly in the induction of 
differentiation of APL cells. Interestingly, the 
normal PLZF protein may be able to interfere 
with binding of Sp1 to the DNA (Lee et al., 
2002), suggesting PLZF-RARα may actively 
repress transcription of this class of genes.
We describe two target genes which are 
upregulated by PML-RARα in response 
to ATRA, by this gain-of-function. One 
of these target genes is ID1. We show that 
overexpression of ID1 in a hematopoietic cell 
line resulted in accumulation of these cells in 
the G0/G1 phase of the cell cycle. C/EBPβ 
may be upregulated by the same mechanism 
as ID1 is. Suppression of C/EBPβ expression 
in NB4 cells, using RNAi, results in a poor 
response of these cells to ATRA (Duprez et al., 
2003). Therefore, both genes may be involved 
in the differentiating effect of ATRA.
An interesting experiment would be 
overexpression of C/EBPβ / ID1 / ID2 in AML 
cells of another FAB-type, and see whether 
these cells will be forced to differentiate. 
Alternatively, an interesting experiment 
would be expression of PML-RARα, in vitro, 
in primary AML cells of another FAB-type, 
and test whether these cells will be forced to 
differentiate and to test which genes become 
responsive to ATRA.
Relapse/ATRA resistant APL patients.
Recent studies show that combined treatment 
of APL patients with ATRA and chemotherapy 
may result in long term disease free survival 
in 80-90% of the cases (Mistry et al., 2003). 
Although this percentage is very high, there 
is still room for improvement. Additionally, 
high dose chemotherapy may result in long 
term effects. Replacing chemotherapy with 
more selective or less genotoxic agents may 
be beneficial for APL patients. The following 
agents may be beneficial in the treatment of 
APL:
1) Durable remission is obtained following 
arsenic trioxide (ATO) treatment as a single 
agent. ATO induces apoptosis via multiple 
pathways and results in degradation of PML-
RARα. The efficacy of ATO is currently under 
investigation. 
2) PML-RARα is able to form stable complexes 
with HDACs, which may contribute to 
transformation by silencing of PML-RARα 
target genes (Grignani et al., 1998; Lin et 
al., 1998). Therefore, antagonizing HDACs 
with HDAC inhibitors, like valproic acid 
(VPA) and trichostatin A (TSA), could have 
potential in the treatment of APL. Recent 
studies have revealed that these inhibitors 
indeed posses antitumor activity (Insinga 
et al., 2005). Surprisingly, the mechanism 
behind this antitumor activity seems not 
dependent on PML-RARα expression but 
rather on the fully transformed phenotype 
of APL cells. Mice expressing PML-RARα 
develop leukemia after a long latency. 
During this latency, blasts of these mice are 
insensitive to HDAC inhibitors. However, 
mice with fully developed APL are sensitive 
to HDAC inhibitors. HDAC inhibitors were 
found to induce apoptosis, in APL blasts, 
by activation of the death receptor pathway, 
through upregulation of TRAIL, DR5, FasL 
and Fas. 
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3) There is evidence for malfunction in the 
p53 pathway in most cancers (Vogelstein 
et al., 2000; Vousden and Prives, 2005). In 
over 50% of the cases this is the result of a 
mutation in the TP53 gene itself. However, 
in leukemia mutations in TP53 are not very 
frequent (Hu et al., 1992). In this thesis we 
show that the MDM2 protein, one ot the 
negative regulators of p53, is upregulated 
by the PML-RARα oncoprotein. Specific 
inhibition of the MDM2-p53 interaction with 
the small molecule inhibitor Nutlin-3, resulted 
in apoptosis of APL blasts. These data indicate 
that Nutlin-3 may have therapeutical potential 
in APL.
4) Yondelis (ET-743) is a potent anti-cancer 
drug isolated from the marine animal 
Ecteinascidia turbinata currently under Phase 
lll clinical trials (D’Incalci and Jimeno, 2003). 
The anti-proliferative activity is more potent 
than taxol or etoposide. Many anti-cancer 
drugs influence gene expression by acting 
on specific promoters. Targets of Yondelis 
include NF-Y target genes. As the response 
to ATRA also includes NF-Y target genes, 
it would be interesting to study the effect of 
Yondelis on APL cells, or APL cell lines in 
vitro. 
Open ends
PML-RARα in gene repression. PML-
RARα, like RARα, functions as a ligand-
activated zinc-finger transcription factor and is 
able to bind to specific sequences in the DNA. 
In the absence of ligand, PML-RARα is able to 
repress gene transcription by the recruitment 
of co-repressors (Alland et al., 1997; Heinzel 
et al., 1997; Nagy et al., 1997), resulting in 
methylation of DNA and deacetylation of 
histones, making the chromatin inaccessible 
to the transcriptional machinery. Active 
repression of target genes may be an important 
mechanism in transformation.
It remains to be investigated whether PML-
RARα, complexed with Sp1-NF-Y, actively 
represses gene transcription by recruitment of 
co-repressors to the gene promoters of ID1. 
We studied the expression levels of ID1 in 
U937 cells, before and after introduction of 
PML-RARα. PML-RARα expression did not 
downregulate ID1 mRNA expression levels. 
However, mRNA expression levels of ID1 
were low, in comparison to expression levels 
after induction with ATRA (data not shown). 
At the protein level ID1 was not detectable in 
U937 cells, suggesting that ID1 may not be a 
good target to study repression.
C/EBPβ has three protein isoforms. The 
smallest isoform of C/EBPβ is detectable in 
U937 cells. This isoform is downregulated 
in response to expression of PML-RARα 
(data not shown). This suggests that PML-
RARα may downregulate C/EBPβ mRNA 
in the absence of ligand, suggesting active 
repression of C/EBPβ. C/EBPβ plays an 
important role in granulocytic differentiation. 
Active repression of C/EBPβ may contribute 
to transformation in APL.
PML. One of the interesting outcomes of our 
studies is that the PML protein is present on 
the promoter of the ID1 gene. PML expression 
has been shown to stimulate transcription of 
several genes. Additionally, PML interacts 
with chromatin remodelling factors, translation 
initiating factor 4E (Borden, 2002) and with 
the transcription factor Sp1 (Vallian et al., 
1998). This suggests that PML may be a 
scaffold factor on the promoter of several 
genes, binding specific transcription factors, 
recruiting chromatin remodelling factors 
and loading the newly produced RNA with 
the first translation initiating factor. Future 
studies will have to determine the precise 
target genes of PML. These data may give 
a better insight into the role of PML in cell 
growth and apoptosis.
NF-Y. Recent studies have revealed that 
repression of several genes, by recruitment of 
HDAC activity to the promoter, is dependent 
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on NF-Y binding sites, suggesting NF-Y is 
directly involved in repression of several 
genes (Imbriano et al., 2005). 
NF-Y may repress genes involved in the 
switch between self-renewal and maturation. 
Subsequently, expression of NF-Y may favour 
self-renewal, as seen upon overexpression 
of NF-Y in BM cells (Zhu et al., 2005) and 
inhibiting NF-Y may favour maturation. 
Moreover, activation of these targets by 
PML-RARα in APL cells upon treatment with 
ATRA may have the same effect as relieving 
the repression by NF-Y through expressing 
dominant negative NF-Y; induction of 
maturation and apoptosis, or in other words; 
terminal differentiation.
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Hoofdstuk 1 (inleiding). Dagelijks worden 
in het menselijk lichaam grote aantallen 
bloedcellen aangemaakt. Deze cellen 
beschermen het lichaam tegen infecties 
(immuniteit), vervoeren zuurstof door het 
lichaam en vormen stolsels bij verwonding. 
Bloedcellen ontstaan vanuit onrijpe cellen in 
het beenmerg. Deze onrijpe cellen worden, 
omdat ze kunnen uitrijpen tot alle verschillende 
soorten bloedcellen, stamcellen genoemd. Dit 
proces heet hematopoïese. In leukemie is 
de uitrijping van cellen geblokkeerd. Deze 
blokkering leidt tot ophoping van onrijpe 
cellen in het beenmerg en het verdringen van 
de normale hematopoïese.
In acute promyelocytenleukemie (APL) is 
de cel geblokkeerd in het stadium van de 
promyelocyt, de cel die normaal gesproken 
uitrijpt tot granulocyt, een celtype betrokken bij 
afweer. APL wordt “acuut” genoemd vanwege 
de snelle progressie van de ziekte welke 
zonder behandeling snel fataal afloopt.
In 1988 publiceerden Huang et al. een studie 
waaruit bleek dat APL patienten gevoelig 
zijn voor een afgeleide stof van vitamine A 
(retinol): all-trans retinoic acid. Deze stof 
dwingt de APL cellen tot terminale uitrijping, 
zowel in vitro als ook in patiënten. Combinatie 
van all-trans retinoic acid met chemotherapie 
leidt bij meer dan 80% van de APL patienten 
tot een overleving langer dan 5 jaar. Dit maakt 
APL, tot op heden, de best behandelbare vorm 
van acute leukemie.
In bijna alle gevallen van APL wordt 
dezelfde genetische afwijking gevonden: 
een uitwisseling tussen de lange armen van 
chromosoom 15 en 17. Deze uitwisseling 
resulteert in een fusie tussen de genen PML, 
op chromosoom 15 en het retinoic acid 
receptor α gen (RARα), op chromosoom 17. 
Expressie van dit fusie-gen in gezonde muizen 
veroorzaakt APL, waarmee wordt aangetoond 
dat PML-RARα het causale oncogen is bij 
deze ziekte. 
RARα codeert voor een ligand-afhankelijke 
transcriptiefactor. RARα bindt specifieke 
sequenties in het DNA en activeert specifieke 
target genen in aanwezigheid van ligand: 
retinoic acid. In APL is de functie van RARα 
verstoord. Het PML-RARα fusie-eiwit is nog 
steeds in staat om specifieke sequenties in het 
DNA te binden. Echter, om genen te activeren 
is voor PML-RARα een meer dan 100 maal 
hogere concentratie retinoic acid nodig dan 
voor RARα. Dit suggereert dat genen die in 
een gezonde situatie geactiveerd worden door 
fysiologische concentraties retinoic acid, bij 
APL niet geactiveerd worden. Behandeling 
van APL patiënten met een hoge dosis retinoic 
acid resulteert wel in activatie van deze genen 
en uitrijping van de leukemische cellen.
Welke genen worden geactiveerd door retinoic 
acid in APL? Antwoord op deze vraag zou 
kunnen helpen het uitrijpingsproces in APL te 
begrijpen en zo mogelijk moleculaire targets 
geven voor onderzoek naar behandeling van 
andere vormen van leukemie. 
De ID1 en ID2 genen coderen voor remmers 
van zogenaamde basic Helix-Loop-Helix 
(bHLH) transcriptiefactoren. Een rol voor ID-
eiwitten en bHLH-eiwitten is aangetoond in de 
uitrijping van verschillende soorten weefsels. 
We onderzochten het effect van ID-eiwitten 
op de uitrijping van APL. Behandeling van 
APL-cellen met retinoic acid resulteerde in 
een directe inductie van ID1 en ID2. Deze 
uitkomst suggereerde een rol voor ID1 en 
ID2 tijdens APL uitrijping. Daarom brachten 
we ID1 en ID2 tot overexpressie in een 
APL-cellijn. Deze overexpressie resulteerde 
in een remming van de proliferatie en een 
ophoping van de cellen in de G0/G1 fase van 
de celcyclus. De data suggereren dat ID1 en 
ID2 een rol spelen bij het therapeutische effect 
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van retinoic acid op APL cellen.
Hoofdstuk 2. Om de rol van PML-RARα 
in de inductie van ID1 te onderzoeken, 
kloneerden we de promoter van ID1 in 
een luciferase reporter construct. Tot onze 
verbazing vonden we dat PML-RARα 
de ID1 promoter kon transactiveren, in 
tegenstelling tot het normale RARα dat de 
ID1 promoter niet kon transactiveren. Dit is 
in tegenspraak met de theorie, die zegt dat 
PML-RARα en RARα dezelfde target genen 
hebben. Om de DNA-sequenties te vinden die 
betrokken zijn bij de transactivatie, maakten 
we verschillende deletiemutanten van de 
ID1 promoter. Deletiemutanten, die alle 
stukken misten die ook maar zijdelings op de 
consensus RARα-binding sequentie leken, 
werden nog steeds getransactiveerd door 
PML-RARα en niet door RARα. Om uit te 
zoeken of PML-RARα de ID1 promoter kon 
transactiveren zonder direct DNA te binden 
gebruikten we een PML-RARα construct 
waar het DNA-binding domein gedeleteerd 
was. Deze PML-RARα mutant was nog steeds 
in staat de ID1 promoter te transactiveren. Dit 
gaf aan dat transactivatie mogelijk gebeurde 
zonder direct DNA contact. Deletie van 
het coiled-coil domein van PML-RARα 
resulteerde in het volledig teniet doen van 
de transactivatie. Aangezien het coiled-coil 
domein betrokken is bij eiwit-eiwit interacties, 
suggereert dit dat de transactivatie afhankelijk 
is van homo-dimerisatie en/of interactie 
met andere eiwitten. Verdere deletie en 
mutatieanalyse van de ID1 promoter toonden 
aan dat een CCAAT-box (bindingsplek voor de 
transcriptiefactor NF-Y) en aangrenzende GC-
box (bindingsplek voor de transcriptiefactor 
Sp1) essentieel waren voor de transactivatie. 
Het verhinderen van de functie van NF-Y, met 
behulp van een dominant negatieve mutant 
van NF-Y, verhinderde de transactivatie van 
de ID1 promoter door PML-RARα. Met 
behulp van GST-pull down experimenten 
werd een interactie tussen PML-RARα 
en Sp1 gevonden, maar geen interactie 
tussen PML-RARα en NF-Y. In chromatine 
immunoprecipitatie assays werd met behulp 
van anti-PML-antilichamen de ID1 promoter 
geprecipiteerd. Gezamelijk wijzen deze 
resultaten op een model waarin PML-RARα 
een Sp1-NF-Y complex bindt op de ID1 
promoter, waardoor de ID1 promoter gevoelig 
wordt voor retinoic acid.
Het effect van PML-RARα op de endogene 
ID1 promoter werd getest in de U937 
cellijn die stabiel getransfecteerd is met 
een Zn2+ induceerbare expressie cassette. 
In aanwezigheid van PML-RARα werd, na 
behandeling met retinoic acid, een versterkte 
respons van ID1 gevonden. 
We tonen tevens aan dat het ID2 gen en 
het HES1 gen, via hetzelfde PML-RARα 
afhankelijke mechanisme als ID1 gereguleerd 
worden. De data impliceren dat PML-RARα, 
naast het dereguleren van RARα target genen, 
een additionele klasse van genen dereguleert. 
Deze ‘gain-of-function’ draagt mogelijk bij 
aan het succesvolle effect van retinoic acid 
in de behandeling van APL.
Hoofdstuk 3. P53 speelt een rol in de inductie 
van celcyclus arrest en apoptose, celdood, 
in genetisch beschadigde cellen. Het p53-
gemedieerde opruimen van cellen is één 
van de belangrijkste mechanismen die ons 
beschermen tegen kanker. Verstoring van de 
p53 functie is een veel voorkomend fenomeen 
in kanker cellen en TP53 is, voor zover nu 
bekend, het meest frequent gemuteerde gen 
in kanker. 
Een negatieve regulator van p53 is 
MDM2. MDM2 bindt p53, verhindert p53 
genen te transactiveren en markeert p53 
voor proteasomale afbraak. In leukemie 
is TP53 zelden gemuteerd, echter, zijn 
functie is mogelijk gedereguleerd door 
andere mechanismen, bijvoorbeeld door 
overexpressie van MDM2.
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We hebben onderzocht of PML-RARα door 
verstoring van MDM2 expressie, de p53 
functie remt. Inductie van PML-RARα in de 
U937 cellijn resulteerde niet in verandering 
van het mRNA expressie niveau van MDM2. 
Inductie van PML-RARα gaf echter wel 
een verhoogd niveau van MDM2 eiwit. Dit 
betekent dat p53 mogelijk gedereguleerd 
wordt in APL cellen door een verhoogd eiwit 
niveau van MDM2.
Een nieuwe klasse van ‘kleine moleculen’, 
Nutlins, is onlangs ontwikkeld. Nutlins 
verstoren de binding van MDM2 met p53, en 
verhinderen daarmee de afbraak van p53 en 
maken p53-afhankelijke apoptose mogelijk. 
We hebben het effect van Nutlins op primaire 
APL cellen getest. Cellen van APL patiënten 
vertoonden een dosis- en tijdsafhankelijke 
toename in apoptose in response tot Nutlins. 
We concluderen dat PML-RARα expressie 
het MDM2 eiwit niveau verhoogt en dat APL 
cellen gevoelig zijn voor Nutlins.
Hoofdstuk 4. Zoals we in hoofdstuk 2 aantonen 
dereguleert PML-RARα target genen van NF-
Y. We hebben daarom de functie van NF-Y 
onderzocht in de hematopoïese. Met behulp 
van retrovirale transductie werd een dominant 
negatieve mutant van NF-Y tot expressie 
gebracht in beenmerg stamcellen van muizen. 
Expressie van deze mutant verhinderde de 
normale functie van NF-Y en remde, in vitro, 
de koloniegroei van granulocyten (CFU-G) 
en monocyten (CFU-M) met respectievelijk 
70% en 44%. 
Om deze remming in detail te bestuderen, 
analyseerden we het effect van dominant 
negatief NF-Y op proliferatie (groei), 
differentiatie (uitrijping) en apoptose 
(celdood). In meer rijpe, MAC-1 positieve, 
cellen was geen verschil te zien in proliferatie, 
differentiatie en apoptose tussen dominant 
negatief NF-Y getransduceerde cellen en 
controle cellen. De expansie van onrijpe, 
MAC-1 negatieve, cellen was volledig 
geremd in dominant  negatief  NF-Y 
getransduceerde cellen en niet in de controle 
cellen. Ook nam apoptose toe in deze onrijpe 
fractie na expressie van dominant negatief 
NF-Y. Competitieve transplantatie van 
beenmergcellen in bestraalde muizen leverde, 
ten opzichte van dominant negatief NF-Y 
getransduceerde cellen, een groei-voordeel op 
voor de controle cellen. De data tonen aan dat 
functioneel NF-Y nodig is voor de expansie 
van onrijpe myeloide cellen.
Hoofdstuk 5. Fluorescence Resonance 
Energy Transfer (FRET) is het fenomeen 
dat een fluochroom (de donor) een ander 
fluochroom (de acceptor) kan exciteren. 
Voorwaarden voor deze energie overdracht 
is dat het emissiespectrum van de donor 
overlapt met het excitatiespectrum van de 
acceptor en dat de donor en acceptor minder 
dan 10 nanometer van elkaar verwijderd 
zijn. Met behulp van FRET-analyse kan 
bestudeerd worden of 2 eiwitten een interactie 
aangaan, door één van deze eiwitten te 
fuseren met een donor- en de ander met een 
acceptorfluochroom. In dit hoofstuk staat 
een techniek beschreven die FRET-analyse 
koppelt aan flow cytometry. Deze techniek 
maakt het mogelijk om, binnen seconden, 
duizenden cellen te analyseren op FRET en 
de cellen op FRET-positiviteit en –negativiteit 
te sorteren, voor mogelijk verdere biologische 
experimenten. 
NF-Y bestaat uit een complex van 3 eiwitten: 
NF-YA, -B en -C. Deze eiwitten moeten 
aan elkaar binden om een een actief NF-Y 
complex te vormen. We tonen aan dat het 
mogelijk is FRET te meten in cellen die 
getransfecteerd zijn met NF-YB en NF-YC, 
gekoppeld aan respectievelijk een donor 
en acceptor fluochroom. Met het boven 
genoemde protocol was het mogelijk de 
FRET-positieve en FRET-negatieve cellen 
te sorteren.
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Acute promyelocytenleukemie en verder 
onderzoek. Ondanks het relatief hoge 
genezingspercentage voor APL, is er nog 
steeds ruimte voor verbetering. Patiënten 
die niet goed reageren op therapie zouden 
mogelijk met andere stoffen geholpen zijn. 
Bovendien worden momenteel nog hoge 
dosis chemotherapie gegeven naast de retinoic 
acid behandeling. Deze behandeling kan 
op lange termijn nog schadelijke gevolgen 
hebben. Vervanging van chemotherapie door 
een selectievere stof, of een minder toxische 
stof, zou verbetering kunnen geven in de 
behandeling van APL patiënten. Voorbeelden 
hiervan zijn:
1) Arsenicum trioxide. APL cellen zijn 
gevoelig voor arsenicum trioxide. Deze stof 
induceert uitrijping van APL cellen en, in 
hogere dosis, apoptose. Behandeling van APL 
cellen resulteert onder andere in afbraak van 
het PML-RARα tumor-eiwit. Momenteel 
wordt de effectiviteit van arsenicum trioxide 
bij de behandeling van APL in verschillende 
studies onderzocht.
2) HDAC remmers. PML-RARα voorkomt 
de activatie van target genen onder meer 
door het rekruteren van HDAC eiwitten. Dit 
mechanisme is betrokken bij de transformatie 
van APL. Het remmen van HDAC eiwitten 
zou daarom potentie kunnen hebben in de 
behandeling van APL. Recente studies hebben 
aangetoond dat een aantal HDAC remmers 
inderdaad antitumor activiteit hebben. Het 
mechanisme achter deze antitumor activiteit 
lijkt echter niet afhankelijk van PML-
RARα expressie, als wel van het volledig 
getransformeerde APL fenotype. HDAC 
remmers induceren apoptose, in APL cellen, 
door middel van het activeren van de ‘death 
receptor pathway’.
3) Nutlins. Er is bewijs voor het niet 
functioneren van p53 in de meeste tumoren. In 
meer dan 50% van de gevallen komt dit door 
een mutatie in het TP53 gen zelf. In leukemie 
komen deze mutaties echter veel minder 
frequent voor. In dit proefschrift laten we 
zien dat de concentratie MDM2, de negatieve 
regulator van p53, verhoogd wordt door het 
PML-RARα tumoreiwit. Specifieke remming 
van de p53-MDM2 interactie, met behulp van 
Nutlins, resulteert in apoptose van APL cellen. 
De data tonen aan dat Nutlins potentie hebben 
voor de behandeling van APL.
4) Yondelis (ET-743) is een veel belovende 
antitumor geneesmiddel. Deze stof wordt 
geïsoleerd uit het zeedier Ecteinascidia 
turbinata en wordt momenteel onderzocht 
in Fase III klinische studies voor soft-tissue 
carcinoma’s. De antiproliferatieve activiteit 
van Yondelis is groter dan die van taxol of 
etoposide. Yondelis beïnvloedt de expressie 
van specifieke genen, onder andere NF-Y 
target genen. Aangezien de NF-Y target genen 
ook betrokken zijn bij de response van APL 
cellen op retinoic acid, zou het interessant 
zijn het effect van Yondelis op APL cellen 
te testen. 
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verdrietig gevoel bij de herinnering aan Arie 
in het ziekenhuisbed, zo dicht bij de afdeling 
waar hij werkte en waar hij de sfeer altijd 
naar een hoger en vrolijker plan probeerde te 
trekken. Arie was een fantastische man en ik 
zal als vriend aan hem blijven denken.
Veel dank ben ik verschuldigd aan de 
begeleiding die ik in Nijmegen heb gehad. Als 
eerste aan Joop Jansen die alle mogelijkheden 
creëerde die ik had en voor de jaren van 
betrokken begeleiding. Bert van der Reijden 
dank ik voor zijn enthousiasme en voor 
het altijd weer aandragen van interessante 
literatuur. 
Er valt voor een bioloog veel te zien en te 
leren wanneer hij in een ziekenhuis komt te 
werken. Onmisbare hulp kreeg ik hierbij van 
mijn promotor Theo de Witte en van Reinier 
Raaijmakers. 
En dan de mensen in het lab:
Gorica, Parel van het Centraal Hematologisch 
Laboratorium (CHL). Je gouden handen en 
strenge gedachten verzekeren het bestaansrecht 
van de conclusies getrokken in dit proefschrift. 
Maar breder, je aanwezigheid maakte heel 
Nijmegen tot een tastbare en warme stad waar 
ik met veel geluk gewoond heb. 
Jurgen, je naam zou niet misstaan onder de 
titel van menig hoofdstuk in dit proefschrift. 
Tegelijkertijd begonnen en al die jaren in 
hetzelfde schuitje - alles besproken wat er 
maar voor viel: wetenschappelijk, sociaal 
en persoonlijk. Misschien waren we wat 
overmoedig en overdadig soms, maar hoe 
zou de wetenschap anders haar voortgang 
vinden?
Elke, verkeerde muzieksmaak, verkeerde kant 
van de paal, verkeerde… nou ja, en toch één 
van de allerleukste collega’s. Hopelijk hebben 
we straks gemeen dat we allebei bij het CHL 
gepromoveerd zijn.
Liesje en Ruth, bedankt voor het proberen mij 
netjes op te voeden in het lab.
Aswin, je onovertroffen vriendelijkheid 
en gulheid zullen een altijd voortdurende 
bewondering bij mij achtergelaten.
Gerty, ouder maar bovenal wijzer. Veel dank 
voor al je enthousiaste hulp tijdens de laatste 
jaren voor je pensioen.
Behalve veel bloed zitten er ook veel zweet en 
tranen van studenten in dit boekje. Esmeralda, 
Ceasar, Jeanette, Joyce, bedankt voor jullie 
inzet maar ook voor de vrolijke noot op het 
lab.
Dank aan al die mensen die vaak dagelijks 
mijn aanwezigheid moesten verdragen; 
Laurens en dokter Sas, Willemijn, Sas1. 
De Cytometrie; Peter, Jan, Rob, Jeroen. De 
Moleculaire Diagnostiek; Marion, Louis, 
Ellen, Evelyn, Laura. En in het bijzonder 
Adrian, dank voor de overgezellige bezoeken 
in je keuken. 
Iman, vier jaar is ongeveer tweehonderd potjes 
tennis. Ik geloof dat ik er niet veel gewonnen 
heb. Hopelijk wonen we na de Postdoc-jaren 
weer dicht genoeg bij elkaar voor revanche 
en zullen we elkaar weer van onze recente 
ontdekkingen versteld doen staan. 
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1.De transcriptiefactor NF-Y is betrokken bij het reguleren van de aantallen 
onrijpe cellen in het lichaam. (dit proefschrift)
2.Het eiwit MDM2 is een mogelijk target voor therapie bij acute 
promyelocytenleukemie. (dit proefschrift)  
3.Het fusie-eiwit PML-RARα heeft meer directe target-genen dan de 
nucleaire receptor RARα. Deze genen zijn betrokken bij differentiatie van 
bloedcellen, en dus mogelijk ook bij het therapeutische effect van ATRA 
in acute promyelocyten leukemie. (dit proefschrift)
4.Algemeen voorkomende mutaties in kanker zijn apoptose en signaal- 
transductie/transcriptie gerelateerd. Apoptose kan alleen in complexe 
meercellige organismen onderzocht worden. Echter, voor een beter 
begrip van signaal-transductie/transcriptie is de ééncellige gist, dankzij 
eenvoudige handelbaarheid en manipuleerbaarheid, het systeem bij 
uitstek. 
5.Niet toevallig is de kloosterling Mendel de oervader van de genetica: 
genetica was en blijft monnikenwerk.
6.Hoe weinig van wat aanvankelijk in de verbeelding bestond wordt ooit 
werkelijkheid.
7.Het publiceren van een papieren versie van een proefschrift is in ons 
digitale tijdperk een dure en achterhaalde traditie.
8.In de weerbarstige werkelijkheid markeert een proefschrift niet zelden 
het einde van een wetenschappelijke carrière.
29. Zowel de blauwdruk van de mens als ook de afdruk van de mens is een 
chromosoom (zie afbeelding Y.Klein).
10.Het dichten van Gerrit Achterberg, in zijn zoektocht naar de geliefde 
dode, is experimenteren in vitro, hetgeen zich in vivo maar niet realiseren 
laat.
11.Niet het vinden, het zoeken is de beloning.
Yves Klein
Anthropometrie
